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WNT signalling has important roles in embryonic development and disease 
(Logan and Nusse, 2004). There are increasing numbers of studies showing that 
WNTs also influence both blood vessel development (angiogenesis) (Dejana, 
2010) and lymphangiogenesis, but the mechanisms how WNTs regulate vessel 
formation have remained vague. In previous studies, it has been shown that 
Wnt5a, a member of the β-catenin-independent Wnt pathway, is essential for the 
development of lymphatic vessels in the dermis of mice (Buttler et al., 2013). At 
embryonic day (ED) 18 Wnt5a-null-mice possess non-functional, highly dilated 
lymphatics, in contrast to functional lymphatics with small lumen observed in 
Wnt5a+/- and wild-type (wt) mice. However, the mechanisms by which Wnt5a reg-
ulates lymphangiogenesis remained unclear. 
 
 
1.1 Structure and function of the lymphatic vas-
cular system 
 
Lymphatic vessels (lymphatics) are in addition to the primary and secondary lym-
phatic organs – thymus, bone marrow, spleen, lymph nodes – an important com-
ponent of the lymphatic system. They can be found in almost all organs and tis-
sues, including perineural structures (Aspelund et al., 2015; Louveau et al., 
2015), but not in cornea, bone marrow and central nervous system (Alitalo et al., 
2005). The lymphatic vascular system is complementary to the cardiovascular 
system and transports extravasated fluid back into the blood stream. Lymphatic 
vessels are, like the blood vessels, lined by endothelial cells (lymphatic endothe-
lial cells - LECs). The smallest vessels are the lymph capillaries, now usually 
called initial lymphatics. They are often blindly ending vessels, or vascular loops, 
with a discontinuous basement membrane and overlapping endothelial junctions, 
which function as delicate interendothelial valves (Baluk et al., 2007; Tammela 
and Alitalo, 2010). Their main function is the drainage of interstitial fluid, and the 
transfer of this fluid (lymph) into larger collecting vessels. These larger, contractile 
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vessels (lymphatic collectors) possess a continuous basement membrane, an in-
tima with semilunar valves, a layer of smooth muscle cells, and an adventitia, 
which contains nerves and nutritive blood vessels (Hasselhof et al., 2016). They 
carry lymph to the lymph nodes (afferent lymphatics). Efferent collectors then ei-
ther drain to a vein or in a lager lymphatic duct, such as the thoracic duct, which 
finally drains into the confluence of the left subclavian and internal jugular vein 
(Wilting and Chao, 2015).  
 
Besides fluid homeostasis, the lymphatics have several other important functions 
such as immune surveillance, and dietary fat absorption in the gut. They play also 
a role in pathological mechanisms like the dissemination and metastasis of lym-
phoma cells and other tumour cells. And in the last years it has also been shown 
that LECs can modulate immune cell activation and function by presentation of 
antigens (reviewed in: Aebischer et al. (2014); Card et al. (2014)). 
 
 
1.2 Vasculogenesis, angiogenesis and lymphan-
giogenesis 
 
Endothelial cells of lymphatic and blood vessels (LECs and BECs) are derived 
from the mesoderm. In the human, the development of blood cells and blood 
vessels starts around the middle of the third week of embryogenesis. At this time, 
mesenchymal haemangioblasts form clusters of cells in the chorion, in the con-
necting stalk and in the yolk sac. These haemangioblasts give rise to blood and 
vessels by forming transient structures called blood island (Pansky, 1982). The 
outer cells of the island differentiate to endothelial cells and the inner ones to 
haematopoietic cells. The blood islands connect to each other by sprouting of the 
endothelial cells, which fuse and form a sinusoidal network. The formation of ves-
sels from angioblasts is called vasculogenesis (Risau and Flamme, 1995), while 
the outgrowth and formation of vessels from pre-existing (sinusoidal or primitive) 




The development of the lymphatic systems starts approximately two weeks later 
than the development of the cardiovascular system (Pansky, 1982). The first vis-
ible signs are the jugular lymph sacs. Already one century ago, there were two 
hypotheses how the lymphatic systems develops. Sabin (1902) stated that the 
lymphatics develop from the endothelium of the cardinal veins, whereas 
Huntington and McClure (1910) stated that they develop from lymphatic vesicles, 
and that theses mesenchymal cells build the wall of the lymph vessels and con-
nect the venous system secondarily. In recent years, our understanding of the 
molecular and cellular mechanisms that regulate the development and function 
of the lymphatic vascular system has grown enormously. In vivo imaging studies 
of zebrafish embryos (Yaniv et al., 2006) and lineage tracing experiments in mice 
(Srinivasan et al., 2007) confirmed Sabins hypothesis, but is has also been 
shown that lymphatics have a non-venous, mesenchymal origin in avian 
(Schneider et al., 1999; Wilting et al., 2006), amphibian (Ny et al., 2005) and 
murine embryos (Buttler et al., 2013; Klotz et al., 2015; Martinez-Corral et al., 
2015). Additionally, there are specialized mesoderm-derived angioblasts in a ve-
nous niche in zebrafish embryos (Nicenboim et al., 2015). 
 
In mice, the development of the lymphatics starts at ED 9.5. At this district time 
point, cells in the cardinal and intersomitic veins start to express Prox1 (Figure 
1A) (Wigle and Oliver, 1999). Around ED 10.5 these cells start to sprout out. This 
process requires the expression of Vascular endothelial growth factor C (Vegf-C, 
the main growth factor for lymphatics) in the surrounding tissue. The sprouting 
LECs then are characterised by expression of the Vascular endothelial growth 
factor receptor 3 (Vegfr-3, the main receptor for Vegf-C), the Lymphatic vessel 
endothelial hyaluronic acid receptor 1 (Lyve-1, mainly expressed on LECs), 
Podoplanin (a highly LEC-specific glycoprotein in the cell membrane), and they 
upregulate the expression of Neuropilin 2 (Nrp2, an alternative receptor for Vegf-
C). Later, these cells form the jugular lymph sacs, which can be observed around 
ED 11.5. 
 
The endothelial cells from the lymph sacs also sprout out and give rise to lym-
phatic vessels, which grow into the periphery. Additionally, lymphangioblasts (in 
the skin, Figure 1B) also differentiate from mesenchymal cells, proliferate and 
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form lymphatic vessels. Later, vessels from both origins interconnect and form 
lymphatic networks (Martinez-Corral et al., 2015). 
 
Figure 1: (A) Schematic model of lymphangiogenesis in the mouse between ED 9.0 and ED 11.5. The 
endothelial cells of the cardinal vein (CV) are the main source of LECs. At ED 9.5 the LEC progenitor cells 
start to express Prox1 and at ED 10.5 they start to bud from the CV and the intersomitic veins. This process 
requires Vegf-C. The differentiating LECs start to express Vegfr-3 and Podoplanin. At ED 11.5 they have 
formed the lymph sacs. (B) Schematic model of lymphangiogenesis in the dermis of mice. Besides sprouting 
from veins (sprouts are positive for Vegfr-3, Prox1, Lyve-1 and Nrp2) there are also non-venous progenitor 
cells (negative for Lyve-1), which proliferate, form vessels and connect to venous-derived vessels. The 




1.3 Angiogenic mechanisms 
 
Angiogenesis is the formation of capillaries from pre-existing vessels (Risau, 
1997). Angiogenic processes transform the primary vascular plexus into a mature 
vascular system with different lumen size and functions. This process is not only 
active during embryonic development, but also present in adult organisms e.g. in 
the female reproductive organs (Modlich et al., 1996) or during wound healing. 
Angiogenesis is strictly regulated. Dysregulated angiogenesis plays important 
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roles in diseases like rheumatoid arthritis, and in cancer. There, tumour cells in-
duce angiogenesis, use the newly formed vessels for oxygen and nutrient supply, 
and also for metastasis formation (Folkman, 1995). 
 
The main mechanisms during angiogenesis are migration and proliferation of en-
dothelial cells. Since the first studies by Folkman and Haudenschild (1980), nu-
merous in vitro assays on angiogenesis have been published. These measure 
proliferation – with proliferation assays, migration – with Boyden chambers or 
scratching/wounding of endothelial monolayers, and differentiation of endothelial 
cells – with 2- and 3-dimensional models, in which endothelial cells form capillary-
like structures on adhesive proteins or in extracellular-matrix-modelling gels (re-
viewed in: WC Liu et al. (2017), Tahergorabi and Khazaei (2012)). 
 
 
1.4 Wnt signalling 
 
WNTs (Wingless-type MMTV integration site family) are secreted lipid-modified 
signalling glycoproteins. They are well conserved across many species (Nusse, 
2005) and until now, 19 different WNT ligands, several receptors and co-recep-
tors have been characterized in the human and in mice. WNTs are involved in 
numerous developmental processes, like embryonic patterning, cell growth, mi-
gration and differentiation, and, as noted above, also angiogenesis is regulated 
by WNT signalling (reviewed e.g. in: Wiese et al. (2018); Dejana (2010)). Dys-
regulation of Wnt signalling causes a variety of diseases, including cancer (re-
viewed in: Katoh and Katoh (2017); Polakis (2012)). 
  
More than 15 receptors and co-receptors are involved in the WNT signalling path-
way, and, together with the 19 WNT ligands, diverse combinations of ligand, re-
ceptor and/or co-receptor are possible (Niehrs, 2012). These combinations can 
activate multiple downstream signalling cascades. Commonly, the pathways are 
divided into two main branches: the ‘canonical’ or -catenin-dependent and the 
‘non-canonical’ or -catenin-independent pathways (Asem et al., 2016). The 
-catenin-independent pathways can then be subdivided into the planar-cell-po-
larity (PCP) pathways and the Ca2+-dependent pathways (Figure 2). However, 
Introduction 
 6 
this classification is only a rough guideline, because all WNT pathways are 
densely interconnected and can also be regulated in a tissue- or cell-type-specific 
manner (Niehrs, 2012).  
 
 
Figure 2: Schematic overview of the main WNT signalling pathways. (a) In the planar-cell-polarity (PCP) 
pathway, WNT activates the small GTPases (RHOA, RAC1), which activate the RHO kinase (ROCK) and/or 
the JUN-N-terminal kinase (JNK). This leads to actin polymerization and is mainly involved in morphogenetic 
movements, motility and cell polarity. (b) In the -catenin-dependent WNT signalling, binding of the WNT 
ligand to the receptor leads to an inactivation of the -catenin “destruction complex” (consisting of adeno-
matous polyposis coli (APC), Axin, the casein kinase Iα (CKIα) and the glycogen synthase kinase 3 (GSK3)), 
which leads to an accumulation of -catenin in the cytosol and to translocation of -catenin into the nucleus. 
There it activates the transcription of WNT target genes. (c) In WNT-Ca2+ signalling, the presence of WNTs 
leads to an activation of the Ca2+- and calmodulin-dependent kinase (CAMKII), protein kinase C (PKC) and 
Calcineurin. Calcineurin activates the transcription factor nuclear factor of activated T cells (NFAT). Both the 
PCP signalling and the WNT-Ca2+ signalling can antagonize the -catenin-dependent WNT signalling. The 
scheme is taken from Niehrs (2012), with permission. 
 
Frizzled (FZD) receptors are the principal WNT receptors and can recruit different 
co-receptors like low-density lipoprotein receptor-related protein 5 (LRP5) and 
LRP6, receptor tyrosine kinase-like orphan receptor (ROR) 1 and ROR2, and the 
related to receptor tyrosine kinase (RYK). LRP5 and LRP6 are usually supposed 
to be involved in the -catenin-dependent WNT signalling, while RORs and RYK 
are involved in -catenin-independent WNT signalling. 
 
WNTs can mediate cell-cell communication during direct cell contact or in a short 
range, due to their lipophilic anchor. They can also act in an autocrine manner 
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(Bafico et al., 2004; Schlange et al., 2007). For secretion of WNTs, a lipid modi-
fication with pamitoleic acid is necessary. This modification is introduced by the 
O-acetyltransferase Porcupine (PORCN) and takes place in the endoplasmic re-
ticulum (ER) (Kurayoshi et al., 2007; Takada et al., 2006). In recent years, small 
molecule inhibitors were produced, which can block the PORCN activity and pre-
vent WNT secretion. These inhibitors may also provide new therapeutic strate-
gies for WNT-driven cancers like melanoma or breast cancer (J Liu et al., 2013; 
Proffitt et al., 2013).  
 
 
1.4.1 The ‘canonical’ or -catenin-dependent WNT sig-
nalling 
 
The -catenin-dependent WNT pathway is the best characterised WNT pathway. 
For this reason, it is often also called the canonical WNT pathway. WNT1, 
WNT3A, and WNT8 are commonly thought to activate this pathway (Kikuchi et 
al., 2011), and LRP5/6 act as co-receptors in this pathway (X. He et al., 2004). 
The presence of canonical WNTs leads to an inhibition of the glycogen synthase 
kinase 3 (GSK3). One of the substrates of GSK3 is -catenin. If GSK3 is not 
inhibited, -catenin gets phosphorylated, which leads to its proteasomal degra-
dation. Thereby, the inactivation of -catenin involves a “destruction complex” 
made up of GSK3, Adenomatous polyposis coli (APC), Axin and the Casein ki-
nase Iα (CKIα). In the presence of WNTs GSK3 is inhibited. Then, -catenin ac-
cumulates in the cytosol, enters the nucleus and associates with transcription 
factors like the T-cell factor (TCF) and Lymphoid enhancer-binding factor (LEF). 
This regulates the transcription of WNT target-genes like CyclinD1 or MYC (Fig-






1.4.2 The ‘non-canonical’ or -catenin-independent WNT 
signalling pathways  
 
All WNT-regulated pathways that do not use -catenin are commonly summa-
rised under the term ‘non-canonical’ or -catenin-independent WNT signalling 
(Niehrs, 2012) and can be subdivided into the planar-cell-polarity (PCP) and the 
Ca2+-dependent pathway (Figure 2a, c). Typical WNTs that activate the 
-catenin-independent pathways are WNT5A and WNT11 (Kikuchi et al., 2011), 
and ROR1/ROR2 and RYK are typical co-receptors (Ho et al., 2012). The PCP 
pathway has often been studied. In the presence of WNTs, that activate the PCP, 
the small GTPases Ras Homolog Family Member A (RHOA) and/or Ras-related 
C3 botulinum toxin substrate 1 (RAC1) are activated, which then activate Rho-
associated coiled-coil containing protein kinase (ROCK) and/or JUN-N-terminal 
kinase (JNK). 
 
WNT-Ca2+-signalling is the second -catenin-independent WNT pathway. There, 
the presence of WNT leads to an activation of G-proteins, which activate Phos-
pholipase C (PLC). PLC cleaves Phosphatidylinositol 4,5-bisphosphate (PIP2) 
into Diacylglycerol (DAG) and Inositol trisphosphate (IP3). IP3 triggers Ca2+ re-
lease from the ER. The increasing Ca2+ concentration activates effectors like the 
Ca2+- and Calmodulin-dependent kinase (CAMKII), Protein kinase C (PKC) and 
Calcineurin, which can activate the transcription factor Nuclear factor of activated 
T cells (NFAT). 
 
It is also well established that the -catenin-independent pathways can antago-
nise functions of the -catenin-dependent pathway (Torres et al., 1996). For ex-
ample, is the binding of specific non-canonical ligands to LRP5/6, which do not 
induce phosphorylation of LRP5/6, the basis for mutually antagonistic effects 




1.5 WNT5A and lymphangiogenesis 
 
WNT5A is a specific WNT ligand that usually activates the -catenin-independent 
pathways. It has also been shown that Wnt5a can inhibit the -catenin-dependent 
WNT signalling (Li et al., 2010; Topol et al., 2003; Torres et al., 1996). Thereby, 
Ror2 may act as receptor or co-receptor of Wnt5a (Grumolato et al., 2010; A 
Mikels et al., 2009). Wnt5a-null-mice (constitutive homozygous Wnt5a knock-out, 
Figure 3) display complex phenotypic alterations, including skeletal defects, like 
craniofacial defects and limb shortening (Yamaguchi et al., 1999), and also de-
fects of inner organs like the heart and the intestine, which is massively shortened 
(Cervantes et al., 2009). Interestingly, the phenotype of Ror-knock-out mice is 
similar to that of Wnt5a (Takeuchi et al., 2000; Yamada et al., 2010). However, it 
has also been shown that Wnt5a can activate the -catenin-dependent pathway 
(Mikels and Nusse, 2006; van Amerongen et al., 2012).  
 
There is increasing evidence that WNTs, and foremost WNT5A, plays an im-
portant role in lymphangiogenesis. In mice, a study of our lab has shown that the 
constitutive homozygous knock-out of Wnt5a leads to significant defects in mor-
phology and function of dermal lymphatics (Buttler et al., 2013). However, Muley 
et al. (2017) have shown that the overexpression of Wnt5a in myeloid cells in-
duces only very minor changes in the dermal lymphatics. 
 
The importance of WNTs during lymphangiogenesis has also been shown in 
studies by Nicenboim et al. (2015), who observed that Wnt5b was necessary and 
sufficient for lymphatic cell-fate specification in zebrafish. They also could show 
that this role of Wnt5b is evolutionarily conserved, since the application of 
WNT5B to the culture medium of human embryonic stem cell-derived angioblasts 
induced increased expression of Prospero homeobox protein 1 (PROX1), the 





Figure 3: Typical phenotype of a Wnta5a-null mouse embryo (B, -/-) and a littermate control embryo 
(A, +/+) at ED 15.5. The Wn5a-null mouse shows numerous defects, like craniofacial malformations, limb 
shortening and the lack of the tail. The embryo also has an oedematous appearance and shows petechial 
bleedings in the skin. Scale bar = 200 µm. 
 
 
1.6 Aims of the thesis 
 
Several studies have shown that Wnts are important regulators of angiogenesis, 
and a few studies have shown that they also regulate lymphangiogenesis. How-
ever, the mechanisms how Wnts regulate lymphangiogenesis remained unclear. 
Therefore, the aim of my theses was to study the mechanisms how WNT signal-
ling, and specifically WNT5A, influences lymphangiogenesis in greater detail. I 
focussed on the functions of Wnt5a in the development of dermal lymphatics in 
murine embryos. I studied the cellular mechanisms regulated by WNTs in human 
LECs, and I was interested in signal transduction down-stream of WNT5A in 
LECs. Finally, I sought to study the transcriptional regulation by WNTs in LECs. 
 
To follow these aims, I divided my thesis into the following parts:  
In the first part, I analysed Wnt5a-related signalling in murine embryos and asked 
the following questions: 
 




2. Is the phenotype of dermal lymphatics of Wnt5a-null mice reversible 
through the application of Wnt5a? 
3. Can I change the phenotype of dermal lymphatics of Wild-type mice by 
inhibiting Wnt signalling? 
 
To answers these questions, I characterised the expression of Wnt-related mol-
ecules in dermal lymphatics of embryonic mice using immunofluorescence stain-
ing, and used activators and inhibitors of the Wnt-signalling pathway to influence 
lymphangiogenesis in embryonic murine dermis in a new ex vivo model. 
 
The second part of my thesis deals with the question how WNTs, and mainly 
WNT5A, influence the lymphangiogenic behaviour of human LECs. To gain fur-
ther insight into this, I sought to answer the following questions: 
 
1. Which WNT-related proteins are expressed in human LECs?  
2. Does WNT signalling and especially WNT5A regulate lymphangiogen-
esis in human LECs? And if so, which angiogenic mechanisms are in-
fluenced, and which WNT signalling pathways are activated during 
WNT-related lymphangiogenesis? 
3. Which genes are globally regulated through WNT signalling in human 
LECs? 
 
Therefore, I first characterised LECs with quantitative real-time PCR, Western 
blot and immunocytology. Then, I performed in vitro angiogenesis assays, includ-
ing scratch-assays, tube-formation assays and proliferation assays with LECs 
and analysed the influence of WNTs under these conditions. I also used these 
assays to get deeper insight into the intracellular down-stream signalling of 
WNT5A in LECs. Therefore, I used a variety of small molecule inhibitors of the 
WNT pathways, and also studied the effects of WNT5A application.  
And finally, to analyse the influence of WNT-inhibition on the regulation of gene 
expression in LECs globally, I applied the WNT-secretion inhibitor LGK974 and 
studied the transcriptome with mRNAseq.
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2.1.1 Chemicals, solutions and consumable supplies 
 
Chemicals, solutions and consumables are listed in Table 1 and Table 2. 
 
Table 1: Chemicals or solutions 
Chemical or solution Manufacturer 
Acetic acid, glacial Merck KGaA, Darmstadt, DE 
Acrylamide 30 % (Rotiphorese) Carl Roth, Karlsruhe, DE 
Basal Medium MV 2 PromoCell, Heidelberg, DE 
Bovine serum albumin, Fraction V 
(BSA) 
AppliChem, Darmstadt, DE 
Bradford solution (Roti-Quant) Carl Roth, Karlsruhe, DE 
Bromophenol blue Merck KGaA, Darmstadt, DE 
CellTracker™ Green CMFDA Thermo Fisher Scientific, Waltham, US 
Chloroform Merck KGaA, Darmstadt, DE 
Citric acid Carl Roth, Karlsruhe, DE 
Clarity™ Western ECL Substrate Bio-Rad Laboratories, Hercules, US 
cOmplete™ protease inhibitor Roche, Mannheim, DE 
Coulter Isoton II Diluent 
Beckman Coulter Life Sciences, Indian-
apolis, US 
Crystal violet SERVA, Heidelberg, DE 
Di-sodium hydrogen phosphate an-
hydrous (Na2HPO4) 
AppliChem, Darmstadt, DE 
Dichlorodiphenyltrichloroethane 
(DDT) 
PanReac, AppliChem, Darmstadt, DE 
Dimethyl sulfoxide (DMSO) 
 
Sigma-Aldrich Chemie, Taufkirchen, DE 
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Chemical or solution Manufacturer 
EGM-2 Endothelial SingleQuots Kit Lonza, Basel, CH 
Endothelial Cell Basal Medium-2 
(EBM2) 
Lonza, Basel, CH 
esVEGFR-2 ReliaTech, Wolfenbüttel, DE 
Ethanol - ROTISOLV Carl Roth, Karlsruhe, DE 
Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth, Karlsruhe, DE 
Fast SYBR Green Master Mix  Applied Biosystems, Waltham, US 
Fluorescein isothiocyanate-dextran 
(FITC-Dextran; 2000 kDa) 
Sigma-Aldrich Chemie, Taufkirchen, DE 
Fluoromount-G 
Invitrogen, Thermo Fisher Scientific, 
Waltham, US 
Foetal bovine serum (FBS) / FBS 
Superior 
Biochrom, Berlin, DE 
Formaldehyde solution 37 % Carl Roth, Karlsruhe, DE 
Glutaraldehyde SERVA, Heidelberg, DE 
Glycerol - ROTIPURAN Carl Roth, Karlsruhe, DE 
Glycine (electrophoresis grade) SERVA, Heidelberg, DE 
Growth Medium MV 2 Supplement 
Pack 
PromoCell, Heidelberg, DE 
Hydrogen peroxide 30 % - ROTI-
PURAN 
Carl Roth, Karlsruhe, DE 
Isopropanol Chemsolute, Th. Geyer, Renningen, DE 
Isopropanol - ROTIPURAN Carl Roth, Karlsruhe, DE 
Luminol Sigma-Aldrich Chemie, Taufkirchen, DE 
Matrigel® Matrix Corning Inc., Corning, US 
Methyl cellulose Sigma-Aldrich Chemie, Taufkirchen, DE 
Milk powder Saliter, Obergünzburg, DE 
Omniscript RT Kit  Quiagen, Venlo, NL 
PageRuler™prestaind protein lad-
der 
Thermo Fisher Scientific, Waltham, US 
Paraplast PLUS Leica Microsystems, Wetzlar, DE 
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Chemical or solution Manufacturer 
Penicillin-Streptomycin (cell culture 
grade; 10 000 U/ml) 
Lonza, Basel, CH 
peqGOLD TriFast™ VWR Life science, Radnor, US 
Phosphate buffered saline (PBS) 
(cell culture grade) 
Lonza, Basel, CH 
Ponceau S Merck KGaA, Darmstadt, DE 
Potassium dihydrogenphosphate 
(KH2PO4) 
Carl Roth, Karlsruhe, DE 
Random Hexamer Primer Thermo Fisher Scientific, Waltham, US 
Recombinant RNasin Ribonucle-
ase Inhibitor 
Promega, Madison, US 
RPMI-1640 with L-glumamine Lonza, Basel, CH 
SignalFire™ ECL Reagent Cell Signaling Technology, Beverly, US 
Sodium chloride Carl Roth, Karlsruhe, DE 
Sodium deoxy cholate Carl Roth, Karlsruhe, DE 
Sodium dodecyl sulphate (SDS) Carl Roth, Karlsruhe, DE 
Sodium orthovanadate (SOV) Sigma-Aldrich Chemie, Taufkirchen, DE 
StarPure Agarose StarLab, Hamburg, DE 
Sucrose Carl Roth, Karlsruhe, DE 
sVEGFR-3 ReliaTech, Wolfenbüttel, DE 
Tetramethylethylenediamine 
(TEMED) 
Carl Roth, Karlsruhe, DE 
Tri-Sodium citrate Merck KGaA, Darmstadt, DE 
Tris base USB, Cleveland, US 
Tris HCl Carl Roth, Karlsruhe, DE 
TritonX-100 GERBU, Gaiberg, DE 
Trypsin/EDTA (cell culture grade) Lonza, Basel, CH 
VEGF-C 
Dr. M. Jeltsch; http://research.med.hel-
sinki.fi/cancerbio/jeltsch/Index.html 
Xylene PanReac, AppliChem, Darmstadt, DE 
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Table 2: Consumables 
Consumable Manufacturer 
Blotting paper sheets (330 g/m2) Sartorius AG, Göttingen. DE 
Cell scraper Sarstedt, Nümbrecht, DE 
Chamber slides BD Falcon, Erembodegem, BE 
Cover slips Menzel-Gläser, Braunschweig, DE 
CRYO.S tubes Greiner Bio-One, Frickenhausen, DE 
Falcon tubes 15 ml, 50 ml Sarstedt, Nümbrecht, DE 
Gentle skin - powder-free examination 
gloves 
Meditrade, Bäch, CH 
ImmunoPen Merck Millipore, Billerica, US 
MicroAmp Fast Optical 96-Well Reac-
tion Plate (0.1 ml) 
Applied Biosystems, Waltham, US 
Microscope slides  Labsolute, Th. Geyer, Renningen, DE 
Millicell® cell culture inserts 0.4 µm, 
12 mm 
Merck Millipore, Billerica, US 
Pasteur pipettes Labsolute, Th. Geyer, Renningen, DE 
Pipette tips (w/o filters) 10 µl, 200 µl, 
1000 µl 
Sarstedt, Nümbrecht, DE 
PVDF membranes (pore size 0.45 µm) Carl Roth, Karlsruhe, DE 
Reaction tubes (0.2 ml. 0.5 ml, 1.5 ml, 
2 ml) 
Sarstedt, Nümbrecht, DE 
Superfrost plus, microscope slides Menzel-Gläser, Braunschweig, DE 
Tissue culture dish (6 cm, 10 cm) Sarstedt, Nümbrecht, DE 
Tissue culture plate 12 well, 24 well, 
48 well, 96 well 
Sarstedt, Nümbrecht, DE 
Tissue culture plate 6 well BD Falcon, Erembodegem, BE 
U-bottom 96 well suspension culture 
plate 
Greiner Bio-One, Frickenhausen, DE 
VIVASPIN 2 Centrifugal Concentrator, 
10,000 MWCO PES 
Satorius AG, Göttingen, DE 
µ-Slide Angiogenesis Ibidi, Martinsried, DE 
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2.1.2 Buffers and media 
 
Recipes of buffers and media used in the studies are listed in Table 3. 
 
Table 3: Recipes of buffers and medias 
4 % PFA solution 
10 % formaldehyde solution 37 % 
90 % 0.1 M Sörensen buffer 
6x SDS loading buffer 
350 mM Tris, pH 6.8 
10 % SDS 
36 % glycerol  
9.3 % DTT 
bromophenol blue 
Blocking solution I (BS I) 1 % BSA in PBS 
Blocking solution II (BS II) 3 % BSA in TBS/T 
Blocking solution III (BS III) 5 % BSA in TBS/T 
Blocking solution IV (BS IV) 5 % MP in TBS/T 
Citric acid buffer (pH 6.0) 
Stock solution A: 21.01 g citric acid in 
1 l ddH2O 
Stock solution B: 29.41 g trisodium cit-
rate in 1 l ddH2O 
Working solution: 18 % stock solution 
A + 82 % stock solution B brought to 
1 l with ddH2O 
EBM2 growth medium  
Endothelial Cell Basal Medium-2 + 
EGM-2 Endothelial SingleQuots Kit 
MV2 growth medium 
Basal Medium MV 2+ 
Growth Medium MV 2 Supplement 
Pack 
PBS (10x) 
6.789 g NaCl 
1.478 g Na2HPO4 
0.43 g KH2PO4 
1 l ddH2O 
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Ponceau S staining solution 0.5 % (w/v) Ponceau S 
1 % (v/v) glacial acetic acid 
 
RIPA lysis buffer (stock) 
140 mM NaCl 
1 mM EDTA 
10 mM Tris, pH 8.0 
1 % Triton-X 
0.1 % SDS 
0.1 % sodium deoxy cholate 
RIPA lysis buffer (working solution) 
RIPA lysis buffer (stock) 
1x cOmplete™ protease inhibitor 
1 mM SOV 
RPMI growth medium 
500 ml RPMI 
50 ml FBS 
5 ml Penicillin-Streptomycin 
Running buffer (10x) 
250 mM Tris base 
1.92 M glycine 
1 % SDS 
Sörensen buffer 0.3 M, pH 7,4 
18.2 % Sörensen buffer A  
81.8 % Sörensen buffer B 
Sörensen buffer A 0.3 M KH2PO4 
Sörensen buffer B 0.3 M Na2HPO4 
TBS/T (10x) 
1.5 M NaCl 
0.035 M Tris base 
0.165 M Tris HCl 
1 % Tween-20 
 
Transfer buffer (10x) 
250 mM Tris base 
1.92 M glycine 
Transfer buffer (working solution) 
10 % transfer buffer stock 
20 % methanol 
70 % ddH2O 
 
  




Inhibitors and applied concentrations are listed in Table 4. DMSO was used as 
solvent. 
 
Table 4: Inhibitors 






mie, Taufkirchen, DE 



































Rac GTPase 100 µM 
SP600125 
Santa Cruz Biotech-
nology, Dallas, US 








ROCK1, ROCK2 50 µM 
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2.1.4 Antibodies and dyes 
 
Primary and secondary antibodies, and fluorescence dyes are listed in Table 5. 
All antibodies were diluted in PBS or in blocking solution. 
 









Alexa Fluor® 488 
donkey anti goat 
Life Technologies, 
Eugene, US 
IF: 1:200 donkey BS I 
Alexa Fluor® 488 
donkey anti rabbit 
Life Technologies, 
Eugene, US 
IF: 1:200 donkey BS I 
Alexa Fluor® 488 
goat anti mouse 
Life Technologies, 
Eugene, US 
IF: 1:200 goat BS I 
Alexa Fluor® 488 
goat anti rat 
Life Technologies, 
Eugene, US 
IF: 1:200 goat BS I 
Alexa Fluor® 594 
donkey anti goat 
Life Technologies, 
Eugene, US 
IF: 1:200 donkey BS I 
Alexa Fluor® 594 
donkey anti rabbit 
Life Technologies, 
Eugene, US 
IF: 1:200 donkey BS I 
Alexa Fluor® 595 
goat anti mouse 
Life Technologies, 
Eugene, US 













































































goat BS I 


































rabbit BS I 














IF: 1:500 rabbit BS I 























































WB: 1:5000 mouse BS II 
 
2.1.5 Recombinant WNT5A 
 
Recombinant Human/Mouse Wnt5a was purchased from R&D Systems (Minne-
apolis, US), diluted in PBS with 1% BSA. Activity of the protein was measured by 
R&D by its ability to inhibit Wnt3a-induced alkaline phosphatase production in 
MC3T3-E1 mouse preosteoblastic cells.  




Software is listed in Table 6. 
 
Table 6: Software  
Software Developer 
Adobe Photoshop CS6 Adobe Systems, San José, US 
AngioTool 0.5a Open source, Zudaire et al. (2011) 
AxioVision Release 4.6.3 SP1 Carl Zeiss Microscopy, Jena, DE 
EndNote X7.8 Thomson Reuters, New York City, US 
Fiji, version 2.0.0-rc64/1.51s Open source; Schindelin et al. (2012) 
GNU Octave, version 4.0.3 (with “im-
age” package) 
Open source, Eaton et al. (2017) 
GraphPad Prism 5.03 GraphPad Software, La Jolla, US 
Image Lab™, version 6.0.1 
Bio Rad Laboratories. Inc, Hercules 
US 
Leica Application Suite Advanced Flu-
orescence 2.6.0.7266 
Leica Microsystems, Wetzlar, DE 
Leica Application Suite Advanced Flu-
orescence 3.2.0.9652 
Leica Microsystems, Wetzlar, DE 
Microsoft® Office for Mac 2016 Microsoft Corporation, Redmont, US 
 
  




Equipment is listed in Table 7. 
 
Table 7: Equipment 
Name Manufacturer Instrument 
Axio Imager.Z1 
Carl Zeiss Microscopy, 
Jena, DE 
Microscope 














ing System  
Bio Rad Laboratories. 
Inc, Hercules US 




tific, Waltham, US 
Tissue processor 
Coulter counter Z1 single 
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Name Manufacturer Instrument 
Mikrowellen Herd GT 
8804 
General Technic Microwave oven 
Molecular Devices 
Thermo max microplate 
reader 






















I used the following mice: C57BL/6, and B6;129S7-Wnt5atm1Amc/J (Wnt5a-null-
mice). The Wnt5a-deleted-mice were obtained from the Jackson Laboratory, Bar 
Harbor, USA (JAX stock #004758) and were originally produced by Yamaguchi 
et al. (1999). All mice were kept in the Central Animal Facility of the University 
Medical Centre Göttingen with a 12 h dark-light-cycle, and with water and food 
ad libitum. All rights of the German Animal Welfare Act (TierSchG) and the Ger-
man regulations on the welfare of animals used for experiments or for other sci-
entific purposes (TierSchVersV) were kept. 
 
 
2.1.9 Human dermal lymphatic endothelial cells 
 
Human dermal lymphatic endothelial cells (HD-LECs) from 4 different donors 
(HD-LEC-C2, HD-LEC-C3, HD-LEC-C4 and LEC7) were used. HD-LEC-C2, 
HD-LEC-C3 and HD-LEC-C4 were purchased from PromoCell and cultured in 
MV2. LEC7 were also purchased from PromoCell but cultured in EBM2 with 
250 ng/ml VEGF-C. 
Materials and Methods 
 25 
The initial assays (spheroid assays) were performed with lymphatic endothelial 
cells isolated from tissue of a patient with a lymphatic malformation, also called 
lymphangioma (lymphangioma-derived lymphatic endothelial cells - LY-LECs). 
These cells (LEC2) were cultured in EBM2 with 250 ng/ml VEGF-C. During the 
course of my studies, genetic analyses revealed that these cells possess an ac-
tivating mutation in the PIK3CA gene (Blesinger et al., 2018). Therefore, the main 





2.2.1 Mouse studies 
 
2.2.1.1 Mouse embryo preparation 
 
Pregnant mice were sacrificed and the embryos removed from the uterus at 
ED 15.5-18.5. The amniotic sac and placenta were removed and the embryos 
stored in PBS at 4°C. From each embryo, a specific part of the body was used 
for genotyping. The embryos were subjected to various techniques. For whole 
mount immuno-staining, the skin of the back and the abdomen of the embryos 
was carefully dissected. For ex vivo skin cultures of the skin, ventral and dorsal 





To test the functionality of the superficial lymphatics of the embryos, microlym-
phangiography was performed. It was performed as described in Buttler et al. 
(2013). Therefore, 2000 kDa fluorescein isothiocyanate-dextran (FITC-dextran, 
25 mg/ml in PBS) was injected with a fine glass pipette into the interstitium of the 
paws of the fore and hind limbs at ED 16.5 and ED 17.5. A Leica M205 FA mi-
croscope with ET GFP filter cube (excitation rage 450-490 nm, emission range 
500-550 nm) was used for visualization of FICT-dextran uptake and transport. 
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Photographs were taken directly after application and every 5 minutes for 30 
minutes. Wnt5a-null-embryos were compared to wildtype (wt, +/+) and heterozy-
gous (+/-) littermates with normal phenotype. At least n = 6 embryos of each gen-
otype were studied. 
 
 
2.2.1.3 Ex vivo skin cultures  
 
Development of dermal lymphatics was studied ex vivo. First, 24 well plates were 
prepared. Each well was filled with 500 µl MV2 culture medium containing 1 % 
penicillin/streptomycin. Then, a Millicell® cell culture insert was placed into the 
well and 200 µl MV2 with 1 % penicillin-streptomycin was added onto the insert. 
Skin specimens of approx. 2x2 mm were isolated from ED 15.5 wild-type and 
Wnt5a-null embryos. Corresponding dermal specimens were taken from the right 
and the left side of each embryo, and used as experimental vs. control groups. 
Each skin specimen was separately placed on a cell culture insert with the epi-
dermis facing the insert. All specimens were cultured for 48 h at 37°C and 5 % 
CO2. 
 
To study WNT5A effects, dermis from Wnt5a-null mice was treated with 
500 ng/ml recombinant Wnt5a protein in the culture medium (n = 26). After 24 h, 
10 ng of Wnt5a in 50 µl culture medium were added to each well. In the controls 
(n = 26), 0.1 % BSA was applied with the medium.  
 
To study the effects of the inhibition of Wnt signalling, I used dermis of ED 15.5 
wild-type C57BL/6 mice, and cultured the specimens as described above. For the 
inhibition of Wnt secretion, 25 µM (n = 14) or 50 µM (n = 14) of the porcupine 
inhibitor LGK974 diluted in DMSO was added to the culture medium. In the cor-
responding controls, equal amounts of DMSO were added to the medium. 
 
After 48 h, the dermal lymphatics were studied. For this reason, whole-mount 
staining of the specimens was performed with anti-Lyve-1 antibodies. Nuclei were 
counter-stained with DAPI. The staining procedure is described in 2.2.2.1.  
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Photographs of the lymphatic networks were taken with a Zeiss Axio Imager.Z1. 
For analysis and comparison, the free software AngioTool 0.5a was used. The 






The genotyping followed Version 2.0 of the genotyping protocol provided by the 





2.2.1.5 Preparation of tissues for paraffin sections 
 
Freshly dissected mouse dermis was fixed with 4 % PFA overnight, and trans-
ferred into a tissue processor. There, the tissues were dehydrated and trans-
ferred in warm Paraplast plus (program of the tissue processor: 3 h 70 % ethanol, 
1 h 80 % ethanol, 1 h 90 % ethanol, 1 h 96 % ethanol, 2x 2 h 100 % ethanol, 
1.5 h isopropyl alcohol, 30 min and 2x 45 min xylene, 30 min Paraplast plus and 
7 h Paraplast plus). Afterwards the tissue was transferred and embedded in fresh 
Paraplast plus. After cooling, paraffin sections were cut with a microtome and 
transferred to microscope slides.  
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2.2.2 Staining procedures 
 
2.2.2.1 Whole mount staining of fresh mouse dermis 
 
The skin samples were fixed for 1-2 h with cold PFA (4 % in PBS) for whole mount 
staining and, thereby, carefully flattened with a slotted spatula or two fine forceps. 
After rinsing three times with cold PBS for 15 min, the samples were blocked with 
1 % BSA in PBS (BS I), with gentle agitation at 4°C overnight, and then incubated 
with the primary antibodies in BS I, again with gentle agitation at 4°C overnight. 
In some cases, the blocking step was omitted and the samples were incubated 
only in a solution of the primary antibodies with BS I, with gentle agitation at 4°C 
for 4 days. After rinsing with PBS at 4°C overnight, the samples were incubated 
with secondary antibodies and DAPI on a shaker at 4°C overnight, followed by 
overnight washing. The samples were finally mounted on a glass slide and cov-
ered with Fluoromount-G. 
 
 
2.2.2.2 Immunofluorescence staining of paraffin sections 
 
Slides with paraffin sections were heated for one minute at 42°C on a heating 
plate. The paraffin was removed with two rinsing steps in xylene for five minutes 
each. The slices were rehydrated in descending ethanol series (100 %, 96 %, 
80 %, 60 %, five minutes each) and washed with ddH2O. For some antibodies, 
an antigen-retrieval procedure was used. For this purpose, the slides were boiled 
four times for five minutes with citric acid buffer at pH 6.0 in a microwave oven at 
240 W. After cooling down to room temperature they were washed twice for five 
minutes with ddH2O and three times for five minutes with PBS.  
One section on each slide was separated with an ImmunoPen-line (negative con-
trol) and then all sections were blocked with BS I for one hour at room tempera-
ture in a dark wet chamber. A solution of the primary antibodies in BS I was ap-
plied to all sections, for the negative control only BS I was applied. The slides 
were stored in a dark wet chamber for one hour at room temperature or overnight 
at 4°C. After two rinsing steps, the secondary antibodies together with DAPI were 
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applied to all sections for one hour at room temperature in a dark wet chamber. 
After two rinsing steps, the sections were mounted with Fluoromount-G and cov-
ered with coverslips. 
Photographs were taken with an Axio Imager.Z1 (Zeiss). Photographs of the neg-
ative controls were taken under the same conditions as the objects and served 
as a control for unspecific binding of the secondary antibodies. 
 
 
2.2.3 Studies on lymphatic endothelial cells 
 
2.2.3.1 Cell culture 
 
HD-LECs were cultured in growth medium at 37°C in 5 % CO2. Medium was 
changed every 2-3 days and cells split (ratio: 1:2 - 1:3) at 80-90 % confluence. 
For all experiments only HD-LECs from passages 3-9 were used. Cell numbers 
were determined in a Coulter counter. Therefore, 100 µl of trypsinized cells were 
diluted in 10 ml Isoton 2 and counted. 
 
For cryo-conservation, cells were centrifuged and re-suspended in FBS contain-
ing 10 % DMSO and collected in cryo-tubes. Cells were frozen in cryo-boxes 
containing isopropanol for a constant cooling of approximately 1°C/min, and 
stored for at least 24 h at -80°C. The tubes were then transferred to liquid nitrogen 
for long-term storage. 
 
 
2.2.3.2 Inhibitor pre-treatment of cells 
 
For activation experiments with WNT5A, HD-LECs were pre-treated for 3 (to 4) 
days with 10 µM LGK974. This inhibits all autocrine WNT secretion, which turned 
out to be absolutely necessary to study effects of WNT5A. 
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2.2.3.3 Cell proliferation assay 
 
Proliferation assays were performed as described previously (J. Becker et al., 
2006). 5,000 cells per well were seeded into 96 well culture plates in 50 µl culture 
medium. After 12 h (t0), various substances were applied to the cultures (com-
pared to controls treated with solvent) and the first portion of the cells (6-8 wells) 
was fixed. Every 24 h (t1 = 24 h, t2 = 48 h, t3 =72 h), a further portion of the cells 
was fixed. Cells were stained with crystal violet and extinction measured photo-
metrical with a microplate reader at 570 nm. To study WNT5A effects, 25 µl cul-
ture medium with 500 ng/ml recombinant WNT5A was added to the wells at both 
t1 and t2. All assays were performed with three HD-LEC lines and 6-8 replicates. 
 
 
2.2.3.4 Cell migration studies with scratch assays 
 
The scratch assay is a commonly used assay to measure horizontal cell migra-
tion. 50,000 cells per well were seeded into 24 well plates and grown to conflu-
ence. For better visibility, cells were stained with CellTracker™ Green (CMFDA) 
according to the manufacturer’s instructions before scratching. For this purpose, 
1.5 µM CMFDA were added to serum-free culture medium and incubated for 45 
minutes at 37°C in 5 % CO2. Scratches were then performed with a 100 µl pipette 
tip. Wells were washed with PBS and fresh medium with or without various test 
substances was added to each well. Directly after scratching photographs were 
taken with Leica DMI600B using L5 filter cube (for GFP) and with phase contrast. 
At the microscope, the positions for each scratch were stored. After 24 h, photo-
graphs were taken with phase contrast and L5 filter cube at the same positions. 
 
For quantification of cell migration, the area of the scratch, which was covered by 
cells (closed area) was measured with GNU Octave, version 4.0.3 after 24 h (Fig-
ure 4). GNU Octave was kindly provided by MSc. Adem Saglam. Because of the 
slight variability of the scratches, the width of each scratch was determined in the 
0 h photographs. With the line drawing tool and the “measure” function in Fiji, the 
width of each scratch was determined at three positions. The mean of the meas-
urements was calculated with Excel and classified into categories.  
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Category 1 contained scratches < 500 µm,  
category 2 contained scratches < 600 µm and ≥ 500 µm,  
category 3 contained scratches < 700 µm and ≥ 600 µm,  
category 4 contained scratches < 800 µm and ≥ 700 µm,  
category 5 contained scratches < 900µm and ≥ 800 µm,  
category 6 contained scratches < 1000 µm and ≥ 900 µm, and  
category 7 contained scratches < 1100 µm.  
To reduce variability, categories 1 and 7 were excluded from the analyses. 




Figure 4: Example for scratch assay quantification with GNU Octave. The script provides the percent-
age of the closed area of the scratch, which is 74.76 % in this example. 
 
2.2.3.5 Tube formation assay 
 
Kubota et al. (1988) were the first that noticed that endothelial cells form tube-
like structures when plated on a basement membrane-like matrix. Now, the tube 
formation assay is a widely used assay to study angiogenesis in vitro. The assay 
was performed on ibidi angiogenesis slides, and the protocol provided with the 
slides was optimized for LECs. 10 µl Matrigel were used for coating of the slides 
and allowed to polymerise overnight at 37°C. The next day, 5,000 cells dispersed 
in MV2 (+ test substance or solvent) were seeded in each well.  
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LECs were pre-treated with 10 µM LGK974 for three days, and labelled with 
CellTrackerTM Green CMFDA immediately before the assay. After 9 h, formation 
of networks was documented. The cell-covered area, number of tubes, number 
of branching points and the total tube length were quantified with the WimTube 
analysis software (Onimagin Technologies SCA, Córdoba, Spain). All assays 
were performed with three HD-LEC lines and five replicates. 
 
 
2.2.3.6 Spheroid sprouting assay 
 
The spheroid sprouting assay is a commonly used in vitro angiogenesis assay. 
Korff and Augustin (1998) first provided a protocol for generating spheroids with 
a defined blood endothelial cell number, and this protocol was optimized here for 
LECs. 
For the formation of spheroids, 3,000 LECs in a mixture of 80 % EBM2 and 20 % 
methyl cellulose solution (1,2 % methyl cellulose in EBM2) were seeded in a 
round-bottom 96 well plate. After 24-48 h, the spheroids were harvested with a 
1 ml pipette. The pipette tip was cut off and the spheroids were collected in a 
falcon tube and centrifuged at 500 g for 3 min. The supernatant was discarded. 
The spheroids were dispersed in a mixture of 2 parts EBM2 (plus test substance) 
and 1 part of Matrigel, and 50 µl of this mixture was pipetted onto a flat 96 well 
plate.  
After 30 minutes of polymerisation (solidifying) at 37°C, a photo was taken of 
each of the spheroids (t0) and after 24h later, a second photo was made (t1). The 
assay was performed at least 3 times with at least 5 replicates. 
In some experiments growth factor-reduced conditions were used. For this pur-
pose, no serum was added to the cell culture medium and growth factor-reduced 
Matrigel was used.  
 
To measure both the number of sprouts and the sprout length, I designed a 
method that makes use of a circular grid. I applied the plug-ins “concentric circles” 
and “cell counter” in Fiji. With concentric circles, I produced a grid where the inner 
circle corresponded to the core of each individual spheroid, and all consecutive 
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circles followed at a distance corresponding to 0.5x radius of the core circle (Fig-
ure 5). Next, with cell counter I calculated the intersections of sprouts with the 
circles, starting with circle 1 (circle next to the core circle). Thereby, both left and 
right sides of each sprout crossing the circle are noted; numbers were therefore 
divided by 2. Different colour coding was used with different circles (Figure 5). 
For the analyses, the sprouts in the t1 photos were counted. In photographs of 
spheroids of lymphangioma-derived cells, only the endpoints of the sprouts were 
counted. 
 
                                     
Figure 5: Example for the counting of sprouts with the circular-grid method. Both left and right sides 
of a sprout that intersects a circle, was counted using the cell-counter plug-in of Fiji. Different colours were 
used for the intersections to mark circles of increasing distance. For calculation of sprouts reaching each 
circle, the intersection numbers were divided by 2 (because left end right sides of sprouts were marked). 
 
 
2.2.3.7 Immunofluorescence staining of cells 
 
For immunofluorescence staining, LECs were seeded on chamber-slides and 
grown to 100 % confluence. After fixation with 4 % PFA (1-30 min, depending of 
the antibodies used) and three rinsing steps with PBS, BS I was added for 30 min. 
For detection of nuclear antigens, 0.05 % Tween or 0.1 % Triton-X was added to 
the last rinsing step. Then the chambers were removed. The further staining pro-
tocol was the same as in 2.2.2.2 after the antigen-retrieval.  
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2.2.4 Molecular biology 
 
2.2.4.1 RNA isolation 
 
Total RNA was isolated with peqGOLD TriFast™ according to the manufacturer’s 
protocol. Thereby, cells were washed with cold PBS, lysated with peqGOLD 
TriFast™, mixed with chloroform and centrifuged. The clear, upper phase with 
the RNA was transferred in a new reaction tube and the RNA-precipitation was 
performed with isopropyl alcohol. The isolated RNA pellets were washed with 
ethanol, dissolved in RNAse-free water and the RNA concentration was deter-
mined with BioPhotometer (Eppendorf). 
 
2.2.4.2 Reverse transcription 
 
2 µg of each RNA were mixed with the RT-PCR master mix (Table 8) and filled 
up with water to a final volume of 20 µl. The samples were then placed into the 
thermocycler (and reverse transcription of mRNA to cDNA occurred). 
Programme of the thermocycler: 60 min - 37°C, 10 min - 70°C, 4°C ∞. 
 
Table 8: Formulation of RT-PCR master mix 
2 µl Buffer 
2 µl dNTPs 
2 µl Random Primer Mix (0.2 µg/ml) 
1 µl Omiscript 
0.5 µl RNase 
 
 
2.2.4.3 Semi-quantitative real-time PCR (qRT-PCR) 
 
The qRT-PCR was performed with SYBR Green in a StepOnePlus Real-Time 
PCR System.  
SYBR Green binds to the double-stranded DNA and causes fluorescence. Every 
PCR cycle doubles the amount of target DNA and fluorescence is measured after 
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every cycle. Increase of fluorescence-intensity is directly dependent on the 
amount of amplified DNA and allow therefore quantification. The first cycle where 
intensity exceeds background fluorescence is called the “threshold cycle” or CT. 
So, a lower CT-value reflects more initially available template cDNA which corre-
sponds to mRNA levels. 
For relative quantification of the PCR products, not only the amount fluorescence 
of the target gene but also of a reference transcript (here β-actin) is measured to 
ensure equal abundance of total RNA in the samples. According to the ∆∆CT -
Method, each sample value is subtracted from the value of the respective value 
of the reference transcript (∆CT). For comparison, one of the samples is defined 
standard and all Sample values (including itself) are subtracted by this value 
(∆∆CT; resulting in 0 for the standard sample). By calculating 2-∆∆CT the standard 
becomes 1 (20) and the expression levels of the other samples become values 
higher than one (in case of higher expression) or lower than one (in case of re-
duced expression compared to the standard sample) (Livak and Schmittgen, 
2001).  
 
For the PCR reaction and the simultaneous fluorescence detection, the detection 
system and corresponding 96 well plates were used.  
For each reaction 10 μl Fast SYBR Green Master Mix, 0.1 µl primer (concentra-
tion 0.01 nmol/µl, forward and revers primers mixed) and 5 µl cDNA, which cor-
relates to 10 ng RNA, were mixed and filled up with water to a final volume of 
15 μl. The cDNA was diluted 1 to 10 for qRT-PCR. 
 
All analyses were performed in triplicates. The corresponding qRT-PCR pro-
gramme is shown in Table 9. 
 
Table 9: qRT-PCR programme 
Initial Denaturation  95°C/20 sec  
Denaturation and Elongation  95°C/3 sec 60°C/30 sec (40 cycles)  
Melt Curve Stage 95°C/15 sec 60°C/1 min 95°C/15 sec  
 
The primers used for qRT-PCR are listed in Table 10 and have been generated 
by IBA GmbH (Göttingen, DE).   
Materials and Methods 
 36 
Table 10: Primers 
Primer Sequence 
AKTIN Fwd: 5’ TCC CCC AAA GTT CAC AA 3’ 
Rev: 5’ AGG ACT GGG TTC TCC TT 3’ 
DDK1 Fwd: 5’ GCA CCT TGG ATG GGT ATT CCA 3’ 
Rev: 5’ GCA CAG TCT GAT GAC CGG AG 3’ 
FZD3 Fwd: 5’ ACG TGA TGG CAG GTA CAC G 3’ 
Rev: 5’ TGA CAT GCT GCC ATG AGG TA 3’ 
FZD4 Fwd: 5’ GAC AAC TTT CAC ACC GCT CA 3’ 
Rev: 5’ TGC ACA TTG GCA CAT AAA CA 3’ 
FZD5 Fwd: 5’ CTG GGG ACT GTC TGC TCT TC 3’ 
Rev: 5’ GAC GGT TAG GGC TCG GAT T 3’ 
FZD6 Fwd: 5’ TGG GTC TCT GAT CAT TGT CG 3’ 
Rev: 5’ TTC TGG TCG AGC TTT TGC TT 3’ 
FZD8 Fwd: 5’ GAT GGG ATT GCA CGG TTT GG 3’ 
Rev: 5’ CCC GTA TTT ACG TGG GGT GT 3’ 
IGF1 Fwd: 5’ ACT AGC AGT CTT CCA ACC CA 3’ 
Rev: 5’ TGG TGT GCA TCT TCA CCT TCA 3’ 
LRP5 Fwd: 5’ GAC AAC GGC AGG ACG TGT AA 3’ 
Rev: 5’ AGA TCC TCC GTA GGT CCG TC 3’ 
LRP6 Fwd: 5’ CTC CGG CGA ATT GAA AGC AG 3’ 
Rev: 5’ TAA GTC CCA CAG GCT GCA AG 3’ 
PRICKLE1 Fwd: 5’ AAC CAG AGC AAA GTG TTC GG 3’ 
Rev: 5’ TGG CCT TGG CTT GTT TTC TC 3’ 
PRICKLE3 Fwd: 5’ CAT CTC CGA CGA CGA CTC AG 3’ 
Rev: 5’ CTC TGG GAG GCA GCT GAA AA 3’ 
ROR1 Fwd: 5’ CAA CAA ACG GCA AGG AGG TG 3’ 
Rev: 5’ ACT CTG GAC TTG CAG TGG GA 3’ 
ROR2 Fwd: 5’ GAC CCT TTA GGA CCC CTT GA 3’ 
Rev: 5’ GGC CTT GGA CAA TGG TGA TA 3’ 
RYK Fwd: 5’ AGT TCG TTG GAT GGC TCT TG 3’ 
Rev: 5’ GAG TTC CCA CAG CGT CAC TC 3’ 
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Primer Sequence 
SPTA1 Fwd: 5’ AGG GCT TAC TTT CTG GAT GGA 3’ 
Rev: 5’ TAG TTG ACG CTT CAT CGC CT 3’ 
SPTBN5 Fwd: 5’ AAT GAG TGC ACG ACC AAG GA 3’ 
Rev: 5’ CCC CTG AAG TTT GGT GTT GC 3’ 
VANGL1 Fwd: 5’ CCA AAT TCC GAG CAG CCA AG 3’ 
Rev: 5’ CTG GCC AGT GGC ATT GTT AC 3’ 
VANGL2 Fwd: 5’ CTG TCT ACA ACC CTG CCC TC 3’ 
Rev: 5’ GGT GCT GTT TTC CTC TCC GA 3’ 
WNT11 Fwd: 5’ CTG CAG AGC TCA CCT GAC TT 3’ 
Rev: 5’ GTT GCA CTG CCT GTC TTG TG 3’ 
WNT3A Fwd: 5’ AGT GCC CCA CTC GGA TAC TT 3’ 
Rev: 5’ AAT ACT GTG GCC CAA CAG CC 3’ 
WNT5A  Fwd: 5’ AGG GCT CCT ACG AGA GTG CT 3’ 
Rev: 5’ GAC ACC CCA TGG CAC TTG 3’ 
WNT5B Fwd: 5’ TTC TGA CAG ACG CCA ACT CC 3’ 
Rev: 5’ GGC TGG GCA CCG ATG ATA AA 3’ 
 
 
2.2.5 Protein biochemistry 
 
2.2.5.1 Whole cell lysates 
 
Cells were trypsinized, centrifuged and the pellets washed with PBS containing 
1 mM SOV, and transferred into a reaction tube. This was centrifuged for 10 min 
at 2,000 rpm at 4°C. The supernatant was discarded and the pellet dissolved in 
RIPA lysis buffer (working solution). After 30 min incubation on ice, the tube was 
centrifuged for 15 min at 15,000 rpm at 4°C. The supernatant with the dissolved 
proteins was collected in a new reaction tube. 
 
For the WNT5A stimulation experiments, HD-LECs were lysed directly in the cul-
ture plates.  
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After washing twice with ice-cold PBS + 1 mM SOV, 150-500 µl RIPA lysis buffer 
(working solution) were added to the plates, which were kept constantly on ice. 
After 10 min, the cells were scraped off with a cell scraper and transferred to a 
reaction tube together with the buffer. This was kept on ice for another 20 min. 
After 15 min centrifugation at 15,000 rpm at 4°C, the supernatant with the dis-
solved proteins was transferred to a new reaction tube. 
 
The protein concentration of each supernatant/lysate was measured with Roti-
Quant according to the manufacturer’s instructions. The optical densities were 
measured with the Eppendorf BioPhotometer and the concentrations calculated 
with help of a standard curve performed with BSA as a calibration protein. 
 
 
2.2.5.2 Concentration of supernatants 
 
For verification of WNT5A attendance in supernatants, the supernatants of cells 
were collected (with or without LGK974 the application of 10 µM LGK974) after 
three days.  
In a second method, growth medium of the cells was exchanged with serum-free 
medium (with or without LGK974) and the supernatants were collected after 
24 hours. This was preformed three times, with at least one day of normal growth 
medium between each collection. And at the end the supernatants were com-
bined. 
 
Then all supernatants were concentrated with VIVASPIN 2 Centrifugal Concen-
trator (10,000 MWCO PES) according to the manufacturer’s protocol. The protein 
concentrations were determined with Roti-Quant as described (2.2.5.1). 
 
 
2.2.5.3 SDS-page and Western blot 
 
Proteins were size-fractioned with sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) (Laemmli, 1970). Polyacrylamide gels composed 
of 5 % stacking gel and 10 % (12 % for WNT5A) separation gel were used. 50 μg 
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protein of each sample was mixed with the appropriate amount of 6x sample 
buffer, denatured at 95°C for 5 min, centrifuged for 5 min at 14,000 rpm and then 
loaded onto the gel. PageRuler™prestaind protein ladder was used to determine 
protein sizes. 
Following electrophoresis, the Bio-Rad Tank Blot system was used to transfer 
the proteins to a PVDF membrane. The membranes were soaked with blocking 
buffer for 1 h at room temperature. The membranes were then incubated with 
primary antibodies diluted in the appropriate blocking buffer and gently shaken at 
4°C overnight. After three rinsing steps of at least five minutes each, the mem-
branes were incubated with HRP-conjugated secondary antibodies diluted in the 
appropriate blocking buffer. After another three rinsing steps of at least five 
minutes each, the membranes were incubated with Clarity™ Western ECL Sub-
strate for five minutes and imaged with the ChemiDoc Imaging System. 
 
For the detection of WNT5A, 6x sample buffer without DDT was used. The lysates 
were not denatured with heat and SignalFire™ ECL Reagent was used for de-
velopment of the signal. 
 
 
2.2.6 Statistical analyses 
 
Statistical analyses were performed with GraphPad Prism 5.03. All data sets 
were tested for normality with the Shapiro-Wilk normality test. When all data sets 
of one comparison passed the normality test, they were evaluated with an un-
paired t-test. If one of the relevant data sets was not normally distributed, the 
Mann-Whitney test was used. 
The proliferation assays were analysed with two-way ANOVA with a Bonferroni 





The aim of my studies was to analyse the influence of WNT signalling, and spe-
cifically WNT5A, on lymphangiogenesis. Therefore, I split my thesis into two main 
parts:  
Firstly, I analysed Wnt5a-related signalling in murine embryos. Initial studies on 
dermal lymphatics of Wnt5a-null-mice were published by our lab some years ago 
(Buttler et al. (2013). I characterised the dermal lymphatics of embryonic mice 
with a focus on Wnt signalling in greater detail. And, I applied an activator and an 
inhibitor of the Wnt signalling pathway to murine embryonic dermis to analyse the 
influence of Wnts on dermal lymphatics. 
In the second part of my thesis, I studied the intracellular down-stream signalling 
of WNT5A in human lymphatic endothelial cells (LECs). I characterised the cells, 
performed in vitro angiogenesis assays, and applied activators and inhibitors of 
both the -catenin-dependent and -catenin-independent WNT pathways. Fi-
nally, I analysed the effects of the inhibition of autocrine WNT-signalling on gene 
expression in LECs. 
 
 
3.1 Studies on murine embryos 
 
This part of my thesis focuses on the influence of Wnt signalling on the develop-
ment and function of murine dermal lymphatics.  
 
3.1.1 Immunohistological characterisation of embryonic 
murine dermal lymphatics  
 
First, I analysed dermal lymphatics of mice under the light of Wnt signalling in 
more detail. Therefore, I used whole-mount staining as described in 2.2.2.1. In 
previous studies, our lab has shown that dermal lymphatics of murine embryos 
are positive for Wnt5a (Buttler et al., 2013). I expanded this experimental ap-
proach with numerous antibodies. Staining of tissues with antibodies against 
Results 
 41 
Wnt5a was difficult. I tested three different antibodies (anti-WNT5A (C-16), Santa 
Cruz Biotechnology; anti-WNT5A (H-58), Santa Cruz Biotechnology; anti-
WNT5A, R&D Systems), but only one of them (H-58, Santa Cruz Biotechnology) 
showed convincing results. In line with in situ hybridization data (see: 
http://www.genepaint.org/cgi-bin/mgrqcgi94) Wnt5a is expressed in numerous 




Figure 6: Mice express Wnt5a in their lymphatic vessels. (A) Anti-Wnt5a (red) whole-mount staining of 
dermis of a mouse at ED 18.5 (anti-WNT5A; H-58, Santa Cruz Biotechnology). The lymphatic vessel (lv) 
shows a stronger expression of Wnt5a than the blood vessel (bv). (B) Anti-CD31 staining (green). The lym-
phatic vessel (lv) typically shows weaker expression than the blood vessels (bv). (C) Merged picture. Coun-
ter-staining of nuclei with DAPI (blue).  
 
Frizzleds (Fzd) are high-affinity receptors for Wnt ligands. To characterise the 
expression of Fzd receptors in lymphatic vessels, I stained whole-mounts of mu-
rine dermis with various anti-Fzd antibodies using a double staining protocol with 
endothelial cell-specific antibodies. Thereby, I received the clearest results with 
antibodies against Fzd5 and Fzd8. Co-staining with an endothelial specific anti-
body (CD31) showed that dermal lymphatic vessels of mice express Fzd5 (Fig-
ure 7) and co-staining with Lyve-1 antibodies revealed expression of Fzd8 in der-
mal lymphatics (Figure 8). Thereby, both Fzd receptors are not only expressed 
in the lymphatic vessels, but also in numerous other dermal cell types. My data 
show that major players of the β-catenin-independent Wnt signalling are present 





Figure 7: Lymphatic vessels of mice express Fzd5. (A) Anti-Fzd5 (red) whole-mount staining of murine 
dermis at ED 18.5. The boxes mark Fzd5-positive lymphatic endothelial cell. (B) Anti-CD31 (green) whole-
mount staining of the same specimen. The lymphatic vessels (lv) show the typical weaker expression of 
CD31 than the blood vessels. The boxes mark CD31-positive lymphatic endothelial cell. (C) Merged picture. 
 
 
Figure 8: Lymphatic vessels of mice express Fzd8. (A) Anti-Lyve-1 (red) whole-mount staining of dermis 
of mice at ED 18.5. The endothelial cells of the lymphatic vessel show a strong expression of Lyve-1. (B) 
Anti-Fzd8 (green) whole-mount staining of the same specimen. (C) Merged picture. The Lyve-1-positive 
LECs of the lymphatic vessel are also positive for Fzd8. 
 
Another protein that is often mentioned in the context of planar-cell-polarity is 
Vangl2. Whole-mount double staining of murine dermis with an anti-Vangl2 anti-
body and CD31 revealed that dermal lymphatics express Vangl2 (Figure 9). 
However, like the other investigated proteins, Vangl2 is almost ubiquitously ex-





Figure 9: Lymphatic vessels of mice express Vangl2. (A) Anti-Vangl2 (red) whole-mount staining of der-
mis of mice at ED 18.5. The lymphatic endothelial cells of the lymphatic vessel (lv) express of Vangl2. (B) 
Anti-CD31 (green) whole-mount staining of dermis of mice at ED 18.5. The lymphatic vessel (lv) shows the 
typical weaker expression of CD31 than the blood vessels. (C) Merged picture. The lymphatic endothelial 
cells of the lymphatic vessel (lv) show co-expression of Vangl2 and CD31.  
 
 
3.1.2 Superficial lymphatics of Wnt5A-null mice are mal-
functioning 
 
To analyse the functionality of the superficial lymphatics, 2000 kDa FITC-dextran 
was injected into the interstitial space of the paws of both the front and hind limbs 
of ED 16.5 and ED 17.5 embryos, as described in 2.2.1.2. In healthy appearing 
mice (wt and Wnt5a+/-), FITC-dextran was taken up into the lymphatics immedi-
ately after injection and transported proximally. Thereby, Wnt5a+/- embryos pos-
sess a phenotypically normal appearance and cannot be distinguished from wt-
mice. In contrast, Wnt5a-null-mice are massively malformed. They are character-
ised by craniofacial malformations, limb shortening and the lack of the tail. This 
phenotype was first described by Yamaguchi et al. (1999). Macrophotographs of 
a Wnta5-null mouse embryo and a littermate control can be seen in the appendix 
(Figure A- 1). 
 
Figure 10 shows the embryos after the injection of FITC-dextran. The upper row 
shows the uptake of the of FITC-dextran in an ED 17.5 heterozygous-Wnt5a-
mouse after 2 min, 10 min, 15 min and 30 min. After 15 minutes a second injec-
tion was made into the paw of the lower limb and after another 15 minutes the 
superficial connecting vessel between the lumbar and axillar region was visible 
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(arrowhead in Figure 10). The lower row shows pictures of an injection of FITC-
dextran into the upper limb bud of a Wnt5a-null-mouse (ED 17.5) after 1 min and 
15 minutes. In contrast to the heterozygous mouse no uptake is visible. This 
clearly shows that the lymphatics are malfunctioning and do not drain the tissue. 
 
 
Figure 10: Interstitial injection of 2000 kDa FITC-dextran into the paw of ED 17.5 mouse embryos. 
Upper row: Pictures of a Wnt5a+/- embryo 2 min, 10 min, 15 min and 30 min after the injection. After 
15 minutes a second injection was made in the paw of the lower limb. The arrowhead marks the intercon-
nection of the inguinal and axillary regions. Lower row: Pictures of Wnt5a-null-embryos 1 min and 15 min 
after the injection. 
 
 
3.1.3 Recombinant WNT5A protein rescues maturation 
of dermal lymphatics in Wnt5a-null-mice 
 
Pieces of approximately 2x2 mm of dorsal thoracic dermis of ED 15.5 
Wnt5a-null-mice were cultured and treated with 500 ng/ml recombinant WNT5A 
for 2 days as described in 2.2.1.3. Dermis from the contralateral side was used 
as controls. In contrast to normal dermis, the dermis of Wnt5a-null-mice was oe-
dematous and soft. Both culturing and whole-mount immunostaining was difficult 
and several specimens showed a high background after staining with Lyve-1 an-
tibodies. Therefore, a large number of experiments could not be evaluated. Fi-
nally, from 10 experiments, I was able to compare 7 WNT5A-treated specimens 
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from 4 different embryos, derived from 3 different litters, with corresponding con-
trols. Figure 11 shows representative pictures of the analysed specimens. After 
2-day culture, an immature vascular plexus was visible in the untreated controls. 
The vessels had a large diameter and lots of small “loops” with short connections 
between the individual vessels (Figure 11, upper row). In contrast, after treat-
ment with WNT5A, the vascular network appeared more mature, with thinner and 
longer vessels, with less but larger “loops” and longer interconnections (Figure 
11, lower row). 
 
To quantify the effects, the vessel-covered area and the number of branching 
points of the specimens were analysed with AngioTool 0.5a. The vessel-covered 
area was significantly smaller in the WNT5A-treated dermis (thinner and longer 
vessel = maturation) (Figure 12A, n ≥ 5, Mann Whitney test, p = 0.0025). The 
number of branching points was slightly lower (less and larger “loops” = more 
mature network), but this was statistically not significant (Figure 12B, n ≥ 5, 
Mann Whitney test, p = 0.1038). 
 
 
Figure 11: Ex vivo studies of dermis from ED 15.5 Wnt5a-null mice treated with recombinant WNT5A 
for 2 days. Representative pictures are shown. Lymphatic vessels were stained with anti-Lyve-1-antibody. 




Figure 12: Quantification of ex vivo studies of lymphatics in the dermis of Wnt5a-null mice; controls 
vs. WNT5A-treated. (A) Vessel-covered area in mm2. (B) Number of branching points. The vessel-covered 
area is significantly lower in WNT5A-treated dermis (Mann-Whitney test, ***p ≤ 0.001). 
 
Higher magnifications of the vessels showed that the endothelial cells of the der-
mal lymphatic vessels possessed an elongated shape after the application of re-
combinant WNT5A (Figure 13). 
 
 
Figure 13: Higher magnification of ex vivo studies of dermis from ED 15.5 Wnt5a-null mice treated 
with recombinant WNT5A for 2 days. Representative pictures are shown. Lymphatic vessels were stained 
with anti-Lyve-1-antibody (red), counter-staining with DAPI (blue). The upper row shows controls treated 
with BSA, and the lower row shows specimens after treatment with WNT5A. Application of WNT5A led to 
an elongation of the LECs. Scale bar = 50 µm.  
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Auxiliary finding: dermal lymphatics of Wnt5a-null mice may 
contain blood 
 
During my tests of Wnt5a antibodies, I made the observation that the lymphatic 
vessels of Wnta5-null mice are often filled with blood (Figure 14). This finding 
goes in line with the observation that the Wnt5a-null embryos show numerous 
petechial bleedings in the skin (Appendix, Figure A- 1, upper row). These stud-
ies were performed in cooperation with Jules A. Demanou Toukam, whom I su-
pervised during his medical doctoral thesis at the UMG, Göttingen. 
 
 
Figure 14: Lymphatic vessels of Wnt5a-null mice contain blood. Anti-Lyve-1 staining (red) of a paraffin 
section of the dermis of a Wnt5a-null mouse at ED 18.5. The lymphatic vessels (lv) are filled with blood cells 
(bc). Counter-staining of nuclei with DAPI (blue).  
 
 
3.1.4 Inhibition of Wnt-signalling retards maturation of 
dermal lymphatics in wild-type mice 
 
Pieces of approximately 2x2 mm of dorsal thoracic dermis of ED 15.5 wild-type 
(wt) C57BL/6 mice were cultured and treated with 25 µM or 50 µM Porcupine 
(Porcn) inhibitor LGK974 for 2 days as described in 2.2.1.3. LGK974 completely 
prevents secretion of Wnts (J Liu et al., 2013). The dermal lymphatic vessels of 
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the untreated specimens were thin and only a small number of “loops” and in-
terconnections between individual vessels were visible (Figure 15, upper row). 
The specimens treated with 25 µM LGK974 showed often larger vessel diame-
ters, and occasionally immature “loops” (Figure 15, row in the middle). Inter-
estingly, the specimens treated with 50 µM LGK974 showed many large-diame-
ter vessels with numerous immature “loops” and connections between neigh-
bouring vessels. 14 specimens from 4 mice were quantified. 
Figure 16 shows the vessel-covered area and the number of branching points 
determined with AngioTool 0.5a. Treatment with 25 µM LGK974 did not signifi-
cantly influence the determined parameters (n = 14; vessel-covered area: t-test, 
p = 0.1858; number of branching points: Mann-Whitney test, p = 0.1305). How-
ever, treatment with 50 µM induced a significant increase in both the vessel-cov-
ered area (= larger vessel diameters) (n = 14, t-test, p = 0.0004) and the number 
of branching points (= many immature “loops”) (n = 14, Mann Whitney test, p = 
0.0244). This led to the conclusion that the treatment with LGK974 prevents mat-
uration of dermal lymphatics. 
 
 
Figure 15: Ex vivo studies of lymphatics in the dermis of ED 15.5 C57BL/6 mice treated with the 
Porcn-inhibitor LGK974. Representative pictures are shown. Lymphatic vessels were stained with anti-
Lyve-1-antibody. The upper row shows the 2-day-cultured controls, the middle row shows specimens treated 




Figure 16: Quantification of ex vivo studies of C57BL/6 mouse dermis with the Porcn-inhibitor 
LGK974. Shown are (A) the vessel-covered area in mm2 and (B) the number of branching points. Both are 
significantly higher in dermis treated with 50 µM LGK974 (t-test and Mann Whitney test, *p ≤ 0.05, 
***p ≤ 0.001). 
 
 
3.2 Studies of human Lymphatic Endothelial 
Cells 
 
The second part of my thesis investigated the question how WNTs, and manly 
WNT5A, influence the lymphangiogenic behaviour of human LECs. First, I per-
formed a molecular characterisation of the LECs, which were then used in various 
in vitro lymphangiogenesis assays. 
 
 
3.2.1 Characterisation of Lymphatic Endothelial Cells 
 
In this part of my thesis I characterised HD-LECs under the light of WNT signal-
ling. Therefore, I performed immunocytology, qRT-PCR and Western blot expres-




3.2.1.1 Immunocytology with LEC markers 
 
As a prerequisite for all studies on human LECs, I studied the purity of the cell 
cultures. I tested several LEC lines, which were bought from PromoCell. These 
Results 
 50 
cells are isolated from foreskin and may contain blood vascular endothelial cells 
(BECs) as well. Each cell line represents one individual. Therefore, I wanted to 
perform the assays with at least three LEC lines. Typical markers for human LECs 
are CD31/PECAM1 and the transcription factor PROX1 (Wilting et al., 2002). 
BECs express CD31 higher than LECs, and they do not express PROX1. For all 
further studies, I chose LEC lines, which were almost 100% CD31 and PROX1 
double-positive (Figure 17). This also holds true for the LEC line (LEC2), which 
was isolated in our lab several years ago, and originates from a child suffering 
from lymphangioma (LY-LEC) (Figure 17) (Norgall et al., 2007).  
 
 
Figure 17: Anti-PROX1 and anti-CD31 double staining of LECs. All LECs showed the typical expression 
pattern with PROX1-positive nuclei (red) and CD31-positive cell membranes (green). Counter staining of 





Next, I studied the expression of WNT-related molecules in LECs in greater de-
tail. I analysed the mRNA expression with semi quantitative real-time PCR 
(qRT-PCR). The method (see 2.2.4.3) provides a relative quantification of the 
mRNA expression levels, calibrated to the expression of a house-keeper gene, 
here -actin. For comparison, the expression levels of a pool of a large number 
of cell lines, which we culture in our lab, was set as 'one'. This pool of cells con-
tained neuroblastoma cell lines (where WNT signalling is up regulated in many 
cell lines = positive control; see: Jürgen Becker and Wilting (2018)), as well as 
BECs and LECs. Buttler et al. (2013) had shown that LY-LECs express WNT5A, 
ROR1, ROR2 and RYK. Among many others, I included these molecules in my 
studies, which I performed with the same HD-LECs, which were also used in all 
in vitro angiogenesis assays (HD-LEC-C2, HD-LEC-C3 and HD-LEC-C4). 
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Figure 18 shows the relative expression levels of WNT-related molecules in 
HD-LECs, as compared to the cell-pool, set as 'one'.  
 
The expression levels in the three LEC lines were always lower than in the neu-
roblastoma-containing cell pool; but clear values were measurable with most of 
the probes. Thereby, HD-LEC-C4 constantly showed lowest expression. The 
mRNA expression of the WNT-ligands WNT3A (β-catenin dependent WNT), 
WNT5A and WNT5B (β-catenin independent WNTs) could be verified. Addition-
ally, HD-LECs expressed the WNT receptors FZD3, FZD4, FZD5, FZD6 and 
FZD8, as well as the co-receptors ROR1 and RYK. The cells also expressed the 
mRNA of the PCP signalling-related molecules VANGL1, PRICKLE1, 
PRICKLE3. As well as DKK1, LRP5 and LRP6, which belong to the β-catenin-
dependent signalling pathway. No mRNA expression of WNT11 and ROR2 was 




Figure 18: Relative expression levels of three HD-LEC lines. In all graphs, the relative expression is 
compared to of a pool of various cell lines, consisting of numerous neuroblastoma cell lines and mixed 




3.2.1.3 Western blot and immunocytology 
 
Protein expression of WNT-related proteins was studied with both Western blot 
analyses (see 2.2.5.3) and immunofluorescence staining of cells (see 2.2.3.7). 
The results are shown in Figure 19. All analysed molecules could be detected in 
Western blots and in immunofluorescence stainings (picture of PRICKLE1 immu-
nofluorescence staining can be found in Figure 20). Immunocytology staining of 
WNT5A was not possible in HD-LEC. Three different anti-WNT5A antibodies 
showed no proper staining (tested antibodies: anti-WNT5A (C-16), Santa Cruz 
Biotechnology, anti-WNT5A (H-58) Santa Cruz Biotechnology, anti-WNT5A, 
R&D Systems).  
WNT5A detection in Western blots was possible, but the HD-LEC-C4 cell line 
showed a variable expression of WNT5A (weak expression: Figure 19, strong 




Figure 19: Protein expression analyses of WNT-related molecules in HD-LECs. (A) Western blots 
showing WNT5A, FZD4, FZD5, FZD6, FZD8, PRICKLE1, VANGL1 and VANGEL2 in HD-LECs lysates. Note 
the highly similar expression levels in all three HD-LEC lines. WNT5A expression of HD-LEC-C4 varied in 
the analysed Western blots (see 3.2.1.3). (B) Immunocytology with antibodies against FZD4, FZD5, FZD6, 
FZD8, VANGL1 and VANGl2 in HD-LEC monolayers. All analysed proteins show perinuclear accumulation 




3.2.1.4 Immunocytology of migrating LECs 
 
Several of the above analysed molecules are associated with the WNT-PCP-
pathway, and it has been shown that FZDs, VANGLs and PRICKLs may have a 
polarized localizations in epithelial cells, such Fzd6 and Vangl1 in mouse tracheal 
epithelial cells (Vladar et al., 2012) (reviewed in: Y Yang and Mlodzik (2015)). To 
test this in LECs, I analysed FZD5, VANGL2 and PRICKLE1 with immunofluo-
rescence staining in migrating LECs, using the scratch assay described in 
2.2.3.4. Notably, LECs in the first 3-4 rows adjacent to the scratch presented a 
polarized morphology. Thereby, FZD5 was enriched in the trailing end of the cells 
(Figure 20A and A`), whereas in non-migrating cells there was no accumulation 
of the protein at any side of the cells (Figure 20A``). PRICKLE1 was highly ex-
pressed in the nucleus of all LECs, and additionally, there was a punctate locali-
sation in the cell membrane of the trailing end of migrating LECs (Figure 20B). 
VANGL2 was usually localised in the cytoplasm around the nucleus, but promi-
nently also in a directed, street-like manner in the leading compartment of the 





Figure 20: Scratch assays: FZD5, PRICKLE1 and VANGL2 show a polarized localization in migrating 
HD-LECs. (A –A`) FZD5 is enriched in the trailing end (arrows) of migrating cells. (A``) In non-migrating 
cells of the monolayer there is no polar distribution of FZD5. (B) Besides the strong expression of PRICKLE1 
in the nucleus, there is a punctate staining in the cell membrane of the trailing end of migrating LECs. (C) 
Note strong expression of VANGL2 around the nucleus, and in the leading compartment of the cells towards 
the scratch. Scale bar = 100 µm  
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3.2.2 The PORCN inhibitor LGK974 inhibits WNT5A se-
cretion in HD-LECs 
 
In my in vitro and ex vivo studies I used the small molecule drug LGK974 to pre-
vent the secretion of all WNT proteins, including WNT5A. LGK974 is a highly 
specific inhibitor of PORCN, which is involved in the processing/palmitoylation of 
WNTs (Liu et al., 2013). To test if LGK974 inhibits the secretion of WNT5A in 
HD-LECs I treated the cells with 10 µM of the drug. I collected the supernatants, 
concentrated them with VIVASPIN 2 Centrifugal Concentrators (see 2.2.5.2), and 
also used the cells to prepare cell lysates. By Western blot analyses and appli-
cation of WNT5A-specific antibodies, I analysed if LGK974 had reduced the 
amount of WNT5A in the supernatants. I expected that the amounts of WNT5A 
in the cell lysates remained unchanged (as shown by Liu et al. (2013) for Wnt3a), 
because LGK974 inhibits the palmitoylation of WNTs, which is important for their 
secretion but not for their production. 
 
First, I analysed the amount of WNT5A in two HD-LEC lines, cultured in MV2, 
and treated them for 3 days with 10 µM LGK974 (Figure 21). LGK974 clearly 
inhibited WNT5A secretion (Figure 21B, upper image). The huge amount of BSA 
in the FBS produced a strong band in the supernatants (visible in the Ponceau 
staining at 55 kDa in Figure 21B, lower image). Therefore, the amount of WNT5A 
that had passed the BSA fraction appeared rather small.  
However, in the lysates of these LECs treated for 3 days with 10 µM LGK974, 





Figure 21: LGK974 inhibits WNT5A production and secretion. Western blot analysis of HD-LECs treated 
for 3 days with 10 µM LGK974. Application of LGK974 reduces significantly the amount of WNT5A in cell 
lysates (A) and in supernatants (B). Both β-actin and Ponceau staining are shown as loading controls. Note 
the large fraction of BSA at 55 kDa in the Ponceau staining. 
 
Because of the large BSA fraction in the supernatants, and due to the fact that it 
is not known how many active WNT proteins are present in serum, I also analysed 
supernatants of LECs treated with LGK974 under serum-free conditions. There-
fore, I treated HD-LECs three times for 24 h with LGK974 in serum-free medium, 
pooled all collected supernatants and concentrated them. Again, under these 
conditions 10 µM LGK974 significantly reduced both the amount of WNT5A in the 
cell lysates (Figure 22A) as well as the secretion of WNT5A (Figure 22B). 
 
 
Figure 22: LGK974 inhibits WNT5A in serum-free conditions. Western blot analysis of HD-LECs treated 
three times for 24 h with 10 µM LGk974. Application of LGK974 reduces significantly the amount of WNT5A 
in cell lysates (A) and in supernatants (B). Both β-actin and Ponceau staining were used as loading controls.  
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3.2.3 In vitro Angiogenesis Assays – Measuring the lym-
phangiogenic potential of lymphatic endothelial 
cells 
 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It 
plays an important role in embryonic development, growth and wound healing. It 
plays also an important role in the malignancy of tumours. There are many in vitro 
angiogenesis assays which measure the main angiogenic mechanisms like 
sprouting, migration, proliferation and tube formation. I used three common as-
says and adopted them for LECs. 
 
 
3.2.3.1 Spheroid Assay – Measuring the capability of sprouting  
 
The spheroid assay was performed as described in 2.2.3.6. Initial assays were 
performed with lymphangioma-derived LY-LECs (LEC2). These were then diag-
nosed to have a monoallelic activating mutation of the PIK3CA gene (Blesinger 
et al., 2018). Therefore, in following experiments I used HD-LECs (LEC7) from a 
healthy donor.  
 
 
3.2.3.1.1 Sprouting of LY-LECs is WNT-dependent 
 
Spheroids of LEC2 were produced in round-bottom plates using serum-free 
EBM2, mixed with growth factor-reduced Matrigel and 25 µM LGK974, 25 µM 
WNT-C59 (PORCN inhibitors) or DMSO (as solvent control), and then transferred 
into 96 well plates. Photographs were taken after 0 h and 24 h, and the number 
of endpoints of the sprouts were counted with the cell counter plug-in of Fiji. Rep-
resentative examples are shown in Figure 23. Quantification in Figure 23D 
shows that autocrine WNT-inhibition with Wnt-C59 and LGK974 inhibits the 
sprouting of LY-LECs significantly (Mann Whitney test, Wnt-C59: p < 0.0001, 





Figure 23: Spheroid assay with LEC2. (A-C) Representative pictures of LEC2 spheroid after 24 h. The 
spheroids were transferred in growth-factor reduced Matrigel with 25 µM LGK974 (B), 25 µM Wnt-C59 (C) 
or the corresponding amount of DMSO as control (A). The blue dots mark the counted endpoints. (D) For 
quantification, the number of endpoints of sprouts were counted. Application of LGK974 or Wnt-C59 reduced 
the number of endpoints of sprouts highly significantly (mean with SD, n ≥ 6 spheroids; Mann Whitney test, 
***p ≤ 0.001). 
 
 
3.2.3.1.2 Sprouting of HD-LECs is VEGF-C-dependent 
 
Since the PIK3CA is likely to interact with the WNT-pathway in a manner, which 
is not fully understood, I decided to switch from LY-LECs to healthy HD-LECs. 
First, I used the same experimental conditions as for LY-LECs, but no sprouting 
occurred (Figure 24A). I then tested different conditions and found that growth 
factors (from Matrigel), and especially VEGF-C, are necessary to induce sprout-
ing of HD-LECs. In fact, no sprouting was visible in the absence of VEGF-C (Fig-
ure 24A, not quantified), and sprouting was significantly reduced when 250 ng 
VEGF-C were mixed with soluble VEGF-receptors (esVEGFR-2, sVEGFR-3), 





















3.2.3.1.3 Sprouting of HD-LECs is WNT-dependent 
 
The next step was to analyse if WNTs play a role during sprouting of HD-LECs. 
Therefore, I transferred the HD-LECs in normal Matrigel with 250 ng VEGF-C. 
This induced the sprouting. I used the same PORCN inhibitors (Wnt-C59 and 
LGK974) like in 3.2.3.1.1, which inhibit the autocrine WNT-secretion. I observed 
that in HD-LECs WNTs play an important role during sprouting, because auto-
crine WNT-inhibition with Wnt-C59 and LGK974 inhibits sprouting significantly 
(Figure 25).  
 
For the quantification of sprouting of HD-LECs I designed a specific method, 
which allows not only the quantification of the number of sprouts, but also their 
length (see 2.2.3.6). Figure 25D-I shows the evaluation of WNT secretion-inhib-
ited spheroids. Both, Wnt-C59 and LGK974 significantly reduced the number and 
length of sprouts (Figure 25D-I, n = 21 spheroids; Mann Whitney test:  
Figure 24: VEGF-C is essential for sprouting of HD-LECs. Spheroids were transferred in growth factor-
reduced Matrigel and the influence of VEGF-C was examined after 24h. (A) No sprouting was visible in the 




Type 1: DMSO vs. LGK974 p = 0.0042, DMSO vs. Wnt-C59 p = 0.0116;  
Type 2: DMSO vs. LGK974 p = 0.0009, DMSO vs. Wnt-C59 p = 0.002;  
Type 3: DMSO vs. LGK974 p < 0.00001, DMSO vs. Wnt-C59 p = 0.0002;  
Type 4: DMSO vs. LGK974 p = 0.0005, DMSO vs. Wnt-C59 p = 0.0005;  
Type 5: DMSO vs. LGK974 p = 0.4878, DMSO vs. Wnt-C59 p = 0.4878;  
Total number: DMSO vs. LGK974 p = 0.0011, DMSO vs. Wnt-C59 p = 0.0051). 
Although LGK974 appeared to be more potent when used at the same concen-
tration as Wnt-C59, this effect was not statistically significant (Figure 25I, n = 21 
spheroids; Mann Whitney test, LGK974 vs. Wnt-C59 p = 0.6994).  
 
 
Figure 25: Sprout formation of HD-LEC-spheroids after inhibition of autocrine WNT-secretion. (A-C) 
Representative pictures of spheroids of HD-LECs after 24 h. Spheroids were grown in normal Matrigel sup-
plemented with 250 ng VEGF-C. A circular grid was applied as described in (2.2.3.6). Effects of 25 µM 
LGK974 (B), 25 µM Wnt-C59 (C) or equal amounts of the solvent DMSO (A). (D-I) Quantification of sprouts 
crossing consecutive circles of the grid. The PORCN-inhibitors LGK974 (25 µM) or Wnt-C59 (25 µM) reduce 
sprout number and length significantly (mean with SD, n = 21 spheroids each; Mann Whitney test, *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001). Type 1 sprouts: as long as or longer than the half of the radius of the spheroid core 
(red), Type 2 sprouts: as long as or longer than the radius of the spheroid core (blue), Type 3 sprouts: as 
long as or longer than the 1.5-fold radius of the spheroid core (orange), Type 4 sprouts: as long as or longer 
than the 2-fold radius of the spheroid core (green), Type 5 sprouts: as long as or longer than the 2.5-fold 
radius of the spheroid core (magenta).  
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Next, I studied the effects of recombinant WNT5A protein in the spheroid assays. 
I used HD-LECs (LEC7) and tested if the application of recombinant WNT5A pro-
tein to the Matrigel counteracted the inhibitory effects of LGK974 or Wnt-C59, but 
this was not the case (Figure 26, not quantified, n = 3). However, it is likely that 
WNT5A protein did not readily penetrate the Matrigel to reach the cell surface. I 
therefore used scratch assays to study WNT5A effects. 
 
 
Figure 26: Application of recombinant WNT5A to HD-LEC-spheroids. Representative pictures of sphe-
roids out of HD-LECs are shown. The spheroids were transferred in normal Matrigel with 250 ng VEGF-C 
and with 25 µM LGK974 (B), 25 µM Wnt-C59 (C) or the equal amount of DMSO as control (A). Application 
of recombinant WNT5A to the Matrigel did not alter sprout formation, neither alone (D), nor in inhibitor-
treated spheroids (E-F). 
 
 
3.2.3.2 Scratch Assays – Measuring horizontal migration of 
LECs  
 
The scratch assay is a migration assay which measures horizontal migration of 
monolayers of cells. The assay was performed as described in 2.2.3.4. Normal, 
healthy HD-LECs (HD-LEC-C2, HD-LEC-C3, HD-LEC-C4) were used in these 
assays. I applied various inhibitors to examine the influence of WNT and WNT-
related pathway members on the horizontal migration ability of HD-LECs. I used 
inhibitors that influence either the β-catenin-dependent signalling (via TCF and 
GSK3) or the β-catenin-independent WNT signalling (via ROCK, RAC and JNK).  
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3.2.3.2.1 Horizontal Migration of HD-LECs is controlled by WNT signalling 
 
To examine if WNTs play a role during horizontal migration, I performed scratch 
assays. I applied the PORCN inhibitor LGK974 in two different concentrations 
(10 µM and 25 µM). Both concentrations inhibited migration significantly (Figure 
27 and Figure 28A, n ≥ 33 each; t-test, DMSO vs. LGK974 10 µM p = 0.0203, 
DMSO vs. LGK974 25 µM p < 0.001). In order to test if these effects might be 
induced by differences in proliferation, I performed proliferation assays as de-
scribed in 2.2.3.3. The proliferation assays showed that after 24 h, when the 
scratch assays were analysed, there were absolutely no differences between the 
proliferation rates of the controls and the inhibitor-treated LECs (Figure 28B and 
Table A- 1, n ≥ 21 each; two-way ANOVA with Bonferroni post-hoc test, DMSO 
vs. LGK974 10 µM p = 0.9801, DMSO vs. LGK974 25 µM p = 0.2515). The assay 
also showed that HD-LECs possess a doubling time of approx. 36 h. Therefore, 
it is evident that the effects measured in the scratch assays after 24 h reflect 
alterations in migration, but not proliferation. 
 
 
Figure 27: Inhibition of autocrine WNT-secretion of migrating HD-LECs. Representative pictures of 
scratch assays with HD-LECs treated with solvent or LGK974 in two concentrations (10 µM and 25 µM) after 





Figure 28: Influence of the inhibition of autocrine WNT-secretion on migration and proliferation of 
HD-LECs. (A) Scratch assay: Quantification of scratch closure by HD-LECs after application of two con-
centrations of LGK974 (10 µM and 25 µM) after 24 h. Percentage of scratch closure is shown. Inhibition of 
PORCN with LGK974 reduces migration significantly (n ≥ 33 each; t-test, *p ≤ 0.05, ***p ≤ 0.001). (B) Pro-
liferation studies: After 24 h, 48 h and 72 h LGK974 treatment (10µM and 25µM) no differences occurred as 
compared to DMSO controls after 24 h (mean with SD, n ≥ 21 each, two-way ANOVA with Bonferroni post-
hoc test)  
 
To test if WNT5A is the WNT family member that regulates migration, LKG974 
pre-treated HD-LECs were used in scratch assays and stimulated with 500ng/ml 
recombinant WNT5A protein after the scratch was made. The results are shown 
in Figure 29 and Figure 30A. The application of WNT5A stimulated migration 
significantly (t-test, LGK974pre vs. LGK974pre + WNT5A, p = 0.0042), although 
WNT5A was not able to rescue the inhibitor effects completely (t-test, DMSO vs. 
LGK974pre + WNT5A, p = 0.0058). Best rescue effects of WNT5A were observed 
in LECs pre-treated with 10 µM inhibitor. Importantly, pre-treatment with 10 µM 
LGK974 and application of 500 ng/ml WNT5A to the cells did not influence prolif-
eration (Figure 30B and Table A- 2, n = 24, two-way ANOVA with Bonferroni 
post-hoc test: DMSO vs. LGK974pre: p > 0.9999, DMSO vs. LGK974pre + WNT5A, 
p > 0.9999). 
 
 
Figure 29: Scratch assay: Application of recombinant WNT5A to migrating HD-LECs. The cells were 
pre-treated with either 10 µM or 25 µM LGK974. After scratching, the cells were treated with constant 
amounts of LGK974 and 500 ng/ml recombinant WNT5A. Representative pictures after 0 h (upper row) and 




Figure 30: Effects of recombinant WNT5A protein on migration and proliferation of HD-LECs. (A) 
Quantification of scratch closure in scratch assays with HD-LECs. The cells were pre-treated with either 
10 µM or 25 µM LGK974. After scratching, the cells were treated with constant amounts of LGK974 plus 
500 ng/ml recombinant WNT5A. After 24 h the scratch closure rate was determined. Inhibition with 10 µM 
LGK974 reduced migration significantly (n ≥ 26 each; t-test, ***p ≤ 0.001), which was rescued by the appli-
cation of 500 ng/ml WNT5A (t-test, LGK974pre vs. LGK974pre + WNT5A, **p ≤ 0.01). Cells treated with 25 µM 
LGK974 plus WNT5A showed no improvement of migration (n ≥ 27 each; t-test, ***p ≤ 0.001. (B) Prolifera-
tion studies with LGK974 pre-treated HD-LECs after application of 500 ng/ml recombinant WNT5A for 24, 
48 and 72 h as compared to DMSO controls (mean with SD, n = 24 each, two-way ANOVA with Bonferroni 
post-hoc test: no differences after 24 h). ns = not significant. 
 
The results show that application of 25µM LGK974 had severe effects on LEC 
migration, which could not be rescued with WNT5A protein. In contrast, the ef-
fects of 10µM LGK974 could be significantly reversed by WNT5A.  
 
 
3.2.3.2.2 Horizontal migration of HD-LECs is mediated through the planar-
cell-polarity (PCP) pathway via RAC and JNK 
 
In the next set of experiments, I sought to characterise which arm of the WNT 
pathway was specifically involved in the control of LEC migration. Therefore, I 
applied activators and inhibitors of both the β-catenin-dependent and the 
β-catenin-independent WNT pathways.  
Firstly, I tested an inhibitor (FH535) and two activators (BIO and IM-12) of the β-
catenin-dependent WNT pathway in the scratch assay. Results are shown in Fig-
ure 31 and Figure 32A. FH535, an inhibitor of the β-catenin-dependent WNT 
signalling pathway that antagonises the β-catenin/TCF-mediated transcription, 
did not influence horizontal migration of HD-LECs (n ≥ 37; t-test, DMSO vs. 
FH535: p = 0.2168, DMSO vs. Bio: p < 0.0001, DMSO vs. IM-12: p = 0.0013). In 
proliferation assays the used concentration of FH535 showed an inhibitory effect 
(Figure 32B and Table A- 3, n ≥ 23, two-way ANOVA with Bonferroni post-hoc 
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test after 24 hours: DMSO vs. FH535: p = 0.0161). This is a clear proof that the 
scratch assay only measures migration but not proliferation effects.  
Both activators Bio and IM-12 did not have a significant effect on proliferation 
after 24 hours (Table A- 3, N ≥ 23, two-way ANOVA with Bonferroni post-hoc 
test, DMSO vs. Bio: p = 0.2098, DMSO vs. IM-12: p > 0.9999), but reduced mi-
gration of LECs significantly (Figure 31 and Figure 32A.) 
 
 
Figure 31: Is migration of HD-LECs mediated by β-catenin-dependent WNT signalling? Representative 
pictures of scratch assays with HD-LECs after 0 (upper row) and 24 (lower row) hours are shown. HD-LECs 
were treated with an inhibitor (FH535), and two activators (Bio and IM-12) of the β-catenin-dependent WNT 
signalling. Bio and IM-12 inhibit migration. 
 
 
Figure 32: Activation of the β-catenin-dependent WNT signalling inhibits migration of HD-LECs, but 
does not influence their proliferation. (A) Quantification of the closed area in scratch assays with 
HD-LECs after application of FH535 (β-catenin-dependent WNT signalling inhibitor), Bio and IM-12 (β-
catenin-dependent WNT signalling activators) after 24 hours. Percentage of closed area is shown. Activation 
of β-catenin-dependent WNT signalling with Bio and IM-12 reduces migration significantly (n ≥ 37; t-test, 
**p ≤ 0.01, ***p ≤ 0.001). (B) Proliferation studies with HD-LECs treated with FH535, Bio and IM-12 for 24, 
48 and 72 hours compared to DMSO controls (mean with SD, n ≥ 23, two-way ANOVA with Bonferroni post-
hoc test: inhibition β-catenin-dependent WNT signalling decreases proliferation significantly after 24 h 
(*p ≤ 0.05), whereas activation of β-catenin-dependent WNT signalling does not influenced the proliferation 




In the next step, I studied PCP-pathway-members in greater detail. Therefore, I 
also used small molecule inhibitors. The first pathway member I was interested 
in was ROCK. In many cases ROCK is involved in the regulation of migration 
(Riento and Ridley, 2003). I used two inhibitors (Y-27632 and Fasudil) and tested 
them in scratch assays with HD-LECs (Figure 33 and Figure 34A). Both did not 
influence the migration of HD-LECs (Figure 34A, n ≥ 31; t-test, DMSO vs. 
Y-27632: p = 0.2904, DMSO vs. Fasudil: p = 0.3595).  
I also analysed these inhibitors in proliferation assays. Fasudil did not change the 
proliferation significantly (Figure 34B and Table A- 4, n ≥ 27, two-way ANOVA 
with Bonferroni post-hoc test: DMSO vs. Fasudil: p = 0.7906), but Y-27632 inhib-
ited the proliferation significantly after 24 hours (n ≥ 27, two-way ANOVA with 
Bonferroni post-hoc test: DMSO vs. Y-27632: p = 0.0069).  
 
 
Figure 33: Migration of HD-LECs is independent of ROCK. Representative pictures of scratch assays 
with HD-LECs after 0 (upper row) and 24 (lower row) hours are shown. HD-LECs were treated with two 





Figure 34: Horizontal migration of HD-LECs is independent of ROCK signalling. (A) Quantification of 
scratch closure of HD-LECs after application of the ROCK inhibitors Y-2763 and Fasudil after 24 h. Percent-
age of closure is shown. Inhibition of ROCK does not influence migration (n ≥ 31; t-test, not significant). (B) 
Proliferation studies with HD-LECs treated for 24, 48 and 72 hours with Y-27632 and Fasudil compared to 
DMSO controls (mean with SD, n ≥ 27, two-way ANOVA with Bonferroni post-hoc test: inhibition of ROCK 
with Y-27632 decreases proliferation significantly after 24 h (*p ≤ 0.05), whereas Fasudil did not influence 
proliferation after 24 h. 
 
The next PCP signalling molecule I was interested in was RAC. RAC is also 
known to be involved in the regulation of migration of several cell types (Sadok 
and Marshall, 2014). To investigate the influence of RAC on horizontal migration, 
I used two RAC inhibitors (EHT 1864 and NSC23766) in scratch assays and 
tested their influence on the migration of HD-LECs. The results are shown in Fig-
ure 35 and Figure 36A. Both inhibitors significantly reduced the horizontal mi-
gration (n ≥ 33; t-test, DMSO vs. EHT 1864: p < 0.0001, DMSO vs. NSC23766: 
p < 0.0001).  
I also tested if the inhibitors had an influence on proliferation (Figure 36B and 
Table A- 5). EHT 1864 did not reduce proliferation after 24 hours (n ≥ 24, two-
way ANOVA with Bonferroni post-hoc test: DMSO vs. EHT 1864: p = 0.0621), but 
NSC23766 decreased proliferation significantly (n ≥ 24, two-way ANOVA with 




Figure 35: Migration of HD-LECs is RAC-mediated. Representative pictures of scratch assays with 
HD-LECs after 0 h (upper row) and 24 h (lower row) are shown. HD-LECs were treated with RAC inhibitors 
(EHT 1864 and NSC23766) after scratching. Both inhibited migration significantly after 24 hours. 
 
 
Figure 36: Horizontal migration of HD-LECs depends on RAC signalling. (A) Quantification of scratch 
assays with HD-LECs after application of the RAC inhibitors EHT 1864 and NSC23766 after 24 hours. Per-
centage of closure is shown. Inhibition of RAC significantly reduces migration (n ≥ 33; t-test, ***p ≤ 0.001). 
(B) Proliferation studies with HD-LECs treated for 24, 48 and 72 hours with EHT 1864 or NSC23766 com-
pared to DMSO controls (mean with SD, n ≥ 24, two-way ANOVA with Bonferroni post-hoc test). Inhibition 
of RAC with EHT 1864 did not influence proliferation after 24 h, whereas inhibition of RAC with NSC23766 
decreases proliferation significantly after 24 h, **p ≤ 0.01. 
 
JNK is a downstream signalling molecule of RAC. JNK is also often mentioned in 
the context of migration. So, my next step was to analyse if JNK influences the 
migration of HD-LECs. Therefore, I used two JNK inhibitors (SP600125 and 
JNK-IN-8) and analysed their influence on migration of HD-LECs in scratch as-
says. Figure 37 and Figure 38A show the results. Both, SP600125 and JNK-IN-8 
inhibited the horizontal migration of HD-LECs significantly (n ≥ 26; t-test, DMSO 
vs. SP600125: p < 0.0001, DMSO vs. JNK-IN-8: p < 0.0001).  
I also tested if the inhibitors would have an effect on proliferation (Figure 38B 
and Table A- 6). Both inhibitors did not decrease proliferation significantly after 
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24 hours (n ≥ 31, two-way ANOVA with Bonferroni post-hoc test: DMSO vs. 
SP600125: p = 0.8913; DMSO vs. JNK-IN-8: p > 0.9999). 
 
 
Figure 37: Migration of HD-LECs is JNK-mediated. Representative pictures of scratch assays with 
HD-LECs after 0 h (upper row) and 24 h (lower row) are shown. HD-LECs were treated with JNK inhibitors 
(SP600125 and JNK-IN-8) after scratching, and both inhibited the migration. 
 
 
Figure 38: Horizontal migration of HD-LECs depends on JNK signalling. (A) Quantification of scratch 
assays with HD-LECs after application of the JNK inhibitors SP600125 and JNK-IN-8 after 24 hours. Per-
centage of closure is shown. Inhibition of JNK significantly reduces the migration (n ≥ 26; t-test, ***p ≤ 0.001). 
(B) Proliferation studies with HD-LECs treated for 24, 48 and 72 hours with SP600125 and JNK-IN-8 com-
pared to DMSO controls (mean with SD, n ≥ 31, two-way ANOVA with Bonferroni post-hoc test) Inhibition of 
JNK did not influence proliferation after 24 h. 
 
 
3.2.3.3 WNT5A induces phosphorylation of JNK  
 
The migration studies of HD-LECs with scratch assays had shown that horizontal 
migration of the cells is mediated by RAC and JNK. To analyse if WNT5A can 
directly activate the JNK pathway by inducing JNK phosphorylation, I studied 
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LGK974-pre-treated HD-LECS and stimulated them with 500 ng/ml recombinant 
WNT5A. I prepared cell lysates and studied Western blots for JNK phosphoryla-
tion. Since the supplementation of the growth medium with FBS led to an overall 
phosphorylation of JNK, I starved the cells for 24 h in serum-free medium before 
the WNT5A application. The results clearly show that WNT5A induced a strong 
phosphorylation of JNK after 15 and 30 minutes, whereas after 2 h the level of 
phosphorylation was nearly back to the initial value (Figure 39). This shows ex-
plicitly that WNT5A is a potent activator of JNK in HD-LECs.  
 
 
Figure 39: WNT5A induces phosphorylation of JNK in HD-LECs. Western blot analysis of HD-LEC ly-
sates. HD-LECs were treated with LGK974 for 3 d and starved for 24h in serum-free medium before WNT5A 
application. (A) Application of 500 ng/ml WNT5A induces a transient phosphorylation (p) of JNK (lanes 3-5). 
α-tubulin was used as loading control. (B, C) Relative quantification of p-JNK at 46 kDa and at 54 kDa. 
(Mean ± SD from 3 independent experiments). Note that WNT5A induces a transient phosphorylation of JNK 
after 15 min and 30 min (lanes 3 and 4). 
 
 
3.2.3.4 Tube Formation Assay – WNT5A increases network for-
mation 
 
The tube formation assays were performed as described in 2.2.3.5. Normal, 
healthy HD-LECs (HD-LEC-C2, HD-LEC-C3, HD-LEC-C4) were used and pre-
treated with 10 µM LGK974 for 3 days. For better visibility, cells were labelled 
with CellTracker. The results are shown in Figure 40. LGK974 alone induced 
network formation (n = 15; DMSO vs. LGK974: cell-covered area: Mann Whitney 
test: p = 0.0063, number of tubes: t-test: p < 0.0001, total length of tubes: t-test: 
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p = 0.0004 and number of branching points: t-test: p = 0.0003), which was an 
unexpected result. However, application of WNT5A to the inhibited cells signifi-
cantly improved all measured aspects of network formation like cell-covered area 
(n = 15; DMSO vs. LGK974 + WNT5A: Mann Whitney test: p < 0.0001), number 
of tubes (n = 15; DMSO vs. LGK974 + WNT5A: t-test: p < 0.0001), total length of 
tubes (n= 15; DMSO vs. LGK974 + WNT5A: t-test: p < 0.0001), and number of 
branching points (n = 15; DMSO vs. LGK974 + WNT5A: t-test: p < 0.0001). This 
is also the case for the comparison to the inhibited cells (n = 15; LGK974 vs. 
LGK974 + WNT5A: cell-covered area: Mann Whitney test: p = 0.0059, number of 
tubes: t-test: p = 0.0118, total length of tubes: t-test: p = 0.0021 and number of 
branching points: t-test: p = 0.02). 
 
 
Figure 40: WNT5A increases network formation. (A-C) Representative pictures of tube formation assays 
with HD-LECs 9 hours after seeding. Quantification revealed a significant increase in cell-covered area (D), 
number of tubes (E), total length of tubes (F) and number of branching points after autocrine WNT-inhibition 
with 10 µM LGK974 (for 3 days), and after application of 500 ng/ml recombinant WNT5A to the pre-treated 
cells compared to the solvent control. Note the significant increase of all parameters after WNT5A application 
(n = 15; Mann Whitney test (D) or t-test (E-F), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).  
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3.2.4 mRNA sequencing analyses of LGK974-treated 
HD-LECs 
 
Next, I was interested in the genes that were regulated by WNTs in HD-LECs. 
Therefore, I worked together with the Transcriptome and Genome Analysis La-
boratory (TAL) of the UMG, Göttingen. We performed stranded mRNA sequenc-
ing (mRNAseq) of LGK974-treated vs. non-treated (control) HD-LECs (each 
three HD-LEC lines with two samples each). The treatment group received the 
application of 10 µM LGK974 for three days to inhibit autocrine WNT signalling 
and the controls received equal amounts of the solvent DMSO. All cells were 
grown in MV2 with 5% FBS. The corresponding gene sets were compared and 
differentially regulated genes in HD-LECs without autocrine WNT signalling were 
depicted. This led to the identification of 116 genes differently regulated in the 
treatment group. The top 50 regulated genes are presented in Figure 41. The 





Figure 41: Heatmap of the top 50 differentially expressed genes in HD-LECs treated with 10 µM 
LGK974 compared to DMSO controls. Log2 fold-change is shown.  
 
The obtained data set was also used for a gene set enrichment analysis (GSEA) 
with a tool from the Broad Institute (http://software.broadinstitute.org/gsea/). 
Three gene sets were overrepresented in the gene list and belonged to the gene 
ontology terms (GO)/gene sets: “GO: response to an external stimulus”, “GO: 









Especially the “GO: movement of cell or subcellular component” appeared to be 
of great interest, because it revealed down-regulation of migration-related tran-
scripts after the application of LGK974, which is in line with my experimental stud-
ies (Figure 43).  
 
 
Figure 42: GSEA for the gene set “Movement of cell or subcellular component”. (A) Results of the 
GSEA for the gene set “Movement of cell or subcellular component”. (B) Enrichment plot. (C) Overrepre-




3.2.4.1 Validation of WNT-regulated genes in LECs by qRT-PCR 
 
Three genes (IGF1, SPTA1, and SPTBN5) of the gene set “Movement of cell or 
subcellular component” caught our special attention. Insulin-like growth factor 1 
(IGF-1) is a hormone that has an important role in the growth of the musculo-
skeletal system, as exemplified by the fact that mutations in the gene and its 
receptors cause the Laron Syndrome (mainly visible as dwarfism; reviewed in 
Laron (2004)). SPTA1 and SPTBN5 encode for spectrins, which are cytoskeletal 
proteins important for stability of the cell membrane and migration. 
 
To validate the results of the mRNAseq analysis, I repeated the experiments and 
treated the three HD-LEC lines again for three days with 10 µM LGK974 (vs. 
controls) and analysed the expression of IGF1, SPTA1 and SPTBN5 with 
qRT-PCR. The results are shown in Figure 43. This analysis confirmed the 
mRNAseq results. All three genes were down-regulated in the probes, which 
were treated with LGK974 for autocrine WNT inhibition. 
 
 
Figure 43: Validation of the mRNAseq analysis with qRT-PCR. In a second round, HD-LECs were treated 
in the same way as for mRNAseq analysis and investigated with qRT-PCR. Treatment with 10 µM LGK974 





Wnt signalling is an important regulator of angiogenesis. In several studies, it has 
been shown that many Wnt ligands, their receptors and co-receptors, and also 
several other Wnt-related molecules play essential roles during the development 
and growth of the blood vascular system (reviewed in: Dejana (2010); Olsen et 
al. (2017)). And a small number of studies has also shown that Wnts play im-
portant roles in the regulation of lymphangiogenesis (e.g. Buttler et al., 2013; Cha 
et al., 2016; Muley et al., 2017), but the mechanisms how they regulate the be-
haviour of lymphatic endothelial cells remained unclear. 
 
In my thesis, I have been able to show that dermal lymphatics of murine embryos 
exhibit several Wnt-related molecules and that Wnts and especially Wnt5a are 
important for their development. In my in vitro studies, I could show that this holds 
true also for human lymphatic endothelial cells (LECs), where WNTs have es-
sential functions in the regulation of angiogenic processes like sprouting, migra-
tion and tube formation. Thereby, I could show that WNT5A mediates horizontal 
migration via RAC and JNK. And finally, my global analyses of WNT-regulated 
genes have shown that WNTs control divers of angiocrine pathways in LECs. 
 
 
4.1 Development of murine dermal lymphatics is 
Wnt5a-mediated 
 
That Wnts are important for the development and function of blood and lymphatic 
vessels in mice has been shown in previous studies. For example, Wnt signalling 
is needed for the precise vascular patterning in organs and the remodelling and 
organization of the vasculature in murine embryos (Cattelino et al., 2003; Corada 
et al., 2010; Descamps et al., 2012). Korn et al. (2014) have shown that in mice 
with EC-specific deletion of the pan-Wnt-secretion factor Evenness Interrupted 
(Evi; also known as Wntless, Wls), the regulation of endothelial cell survial, 
proliferation and the vascular density are defective. The cell-specific knock-out of 
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Wls in myeloid cell revealed that Wnts are important for normal development of 
dermal lymphatics (Muley et al., 2017). Additionally, Wnt signalling controls the 
correct formation of lymphatic and lymphovenous valves (Cha et al., 2016) and 
can directly interact with Vegf-C, the vascular endothelial growth factor with high 
specificity for lymphatics (Niederleithner et al., 2012; Sessa et al., 2016). Among 
the 19 WNT ligands, Wnt5a has a special significance for the development of 
blood and lymphatic vessels, which has been shown in studies of mice (Buttler 
et al., 2013; Muley et al., 2017), and in human ECs (Cheng et al., 2008; Cirone 
et al., 2008; Masckauchan et al., 2006).  
 
The mouse-related part of my thesis based mainly on previous observations of 
our lab, published by Buttler et al. (2013). There it was shown that Wnt5a is an 
important regulator of lymphangiogenesis of dermal lymphatics. They analysed 
the initial lymphatics of Wnt5a-null-mice and noted that these vessels were mas-
sively dilated. Compared to the dermal lymphatics of the healthy wild-type litter-
mates the number and diameter of the vessels were significantly altered in the 
Wn5a-null-mice. The authors concluded that these effects occurred due to a mor-
phogenesis defect but not due to proliferation defects, since the number of LECs 
and the total vessel-covered area were not significantly altered in ED 18.5 em-
bryos.  
 
To examine these findings in greater detail, I characterised the expression of sev-
eral Wnt-related molecules in dermal lymphatics of embryonic mice using immu-
nofluorescence staining, analysed the function of initial lymphatics and lymphatic 
collectors in earlier developmental stages, and used a new ex vivo assay to study 
the influence of activators and inhibitors of Wnt-signalling on lymphangiogenesis 
in embryonic murine dermis. 
 
My immunofluorescence staining with several antibodies revealed that the dermal 
lymphatics of mice express Wnt5a, Fzd5, Fzd8 and Vangl2. My findings are in 
line with previous results of our lab, who have shown in tissue slices that LECs 
are positive for Wnt5a. My staining results also support their findings that LECs 




The expression of Fzd5 and Fzd8 is in line with findings of other studies, which 
demonstrate that Fzds are typical receptors for Wnts (Niehrs, 2012). Thereby, 
Fzd5 is a high-affinity receptor for Wnt5a (Dijksterhuis et al., 2015; Xi He et al., 
1997), which is supported by the Reference sequence (RefSeq) database (Ref-
Seq, Jul 2008; (O'Leary et al., 2016)). The expression of Fzd receptors on many 
cell types is not surprising due to the fact that Wnt signalling is a complex system, 
and it has been shown for many cell types in the dermis that they communicate 
via Wnt signalling. 
 
Vangl2 is a protein with important functions in planar-cell-polarity (PCP). It trans-
mits directional signals to individual cells or groups of cells in epithelial sheets 
(Findlay et al., 2016; Gao et al., 2018). LECs are also organised as epithelial 
sheets, and their directed migration seems to be a prerequisite for lymphangio-
genesis.  
 
I also strengthened the functional analysis of Buttler et al. (2013) with further flu-
orescence microlymphangiografic studies of younger mouse embryos. I could 
show that in mice of ED 17.5 the lymphatic vascular system is functional, and that 
in Wnt5a-null-mice of this age interstitially injected FITC-dextran is not trans-
ported centripetally. Thereby, I could demonstrate that mice possess functional 
superficial lymphatic collectors in the dermis of the trunk, which connect the axil-
lary with the inguinal region. This interconnexion is the reason why metastases 
of tumours placed on the hip of nude-mice are regularly found in axillary lymph 
nodes. In the human, comparable collectors do not exist. 
 
In a new ex vivo assay I analysed if WNT5A is capable of rescuing the phenotype 
of dermal lymphatics that occurred through the general loss of the Wnt5a gene. 
The application of recombinant WNT5A protein to ex vivo cultures of dermis from 
ED 15.5 Wnt5a-null mice induced a flow-independent development from an im-
mature plexus into a slender, elongated lymphatic network after two days. This 
maturation was measurable (significant reduction of vessel-covered area) and 
characterized by thinner and longer vessels, with less but larger “loops” and 
longer interconnections. The cell shape in the vessels changed from round in 




Working with dermal specimens from Wnt5a-null mice was difficult, because of 
their soft and oedematous texture. Many of the specimens showed a strong back-
ground after whole-mount immunostaining with anti-Lyve-1 antibody, and finally, 
only one-fifth of the specimens could in the end be used for quantification in com-
parison to the non-treated controls of the contra-lateral side. Although the number 
of quantified specimens was low, results were statistically significant, and, as 
shown in the representative pictures, the changes were very obvious.  
 
With the same type of assay, I also did a reverse experiment. I used the small 
molecule PORCN inhibitor LGK974, which prevents secretion of all Wnt proteins, 
and applied it to wt-mouse dermis. I used two concentrations and the higher one 
(50 µM) induced significant changes. The dermal lymphatic vessels of the un-
treated specimens were more mature. They were thin and only a small number 
of “loops” and interconnections between individual vessels were present. While 
the specimens treated with the lower concentration (25 µM) only occasionally 
showed immature “loops”, the ones treated with the higher concertation regularly 
presented with large-diameter vessels with numerous immature “loops” and con-
nections between neighbouring vessels. I interpret the emerge of larger vessel 
diameters with more and smaller “loops” as a deceleration or stop of maturation.  
 
The defects of the dermal lymphatics in Wnt5a-null mouse embryos seem to oc-
cur through a failure during the elongation of the lymphatics during maturation or 
through a failure of connectivity of the lymphatic vessels. This results in an im-
mature lymphatic plexus and the frequent formation of isolated cyst-like lymphat-
ics, which I could demonstrate by whole-mount staining of dermal lymphatics with 
Lyve-1 antibody.  
My findings suggest that during lymphangiogenesis Wnts have the same or sim-
ilar functions as during early embryogenesis, e.g. during gastrulation. There, the 
effects of Wnts have been summarized as 'convergent extension' (Djiane et al., 
2000; Topczewski et al., 2001). This describes the migration of cells towards 
each other, followed by movements that result in the elongation of a structure, 




The convergence of angioblasts and the extension of a primitive vascular plexus 
into a network are important mechanisms during both (haem)angiogenesis and 
lymphangiogenesis. It has been shown that haemangioblasts emerge from vari-
ous extra- and intra-embryonic compartments, assemble (converge and build the 
so-called blood islands), extend into vascular tubes and form a primitive vascular 
plexus. The lumen of the early vessels is very wide, so they have been assigned 
as sinusoidal, primary or 'primitive'. A variety of mechanisms take place in the 
further development of the vascular plexus, like the integration of more angio-
blasts (convergence), fusion of vessels, sprouting, splitting and intussusception 
(Jain, 2003; Risau, 1997; Wilting et al., 1995). Elongation of vessels (extension) 
is also a widely observed mechanism, but has mostly been called vascular 
branching, pruning, and remodelling (Ribatti, 2006; Risau, 1997). 
 
The same mechanisms obviously also take place during lymphangiogenesis. 
There lymphangioblasts, either originating from veins or from mesenchymal 
sources (e.g. Martinez-Corral et al., 2015) assemble (converge) into primary lym-
phatic networks, which mature (elongate, extend) into lymphatic capillaries and 
collectors. A function for Wnt-signalling during lymphangiogenesis has been 
noted earlier (Buttler et al., 2013; Dejana, 2010; Nicenboim et al., 2015), but the 
significance of convergent extension movements for lymphangiogenesis has not 
been discussed before. My studies clearly support the importance of these mech-
anisms. In the dermal lymphatics of Wnt5a-null-mice these mechanisms are dis-
turbed. Similar defects could also be found in the dermal lymphatics of Wnt5a-
null-mice after ex vivo culturing. There, the application of WNT5A normalised 




4.2 WNT signalling potential of human lymphatic 
endothelial cells 
 
To analyses the potential of WNT signalling during lymphangiogenesis in hu-
mans, I first characterised human, foreskin-derived and lymphangioma-derived 
LECs. Therefore, I used immunocytology, qRT-PCR and Western blot analyses.  
 
With anti-PROX1 and anti-CD31 staining of LECs I could demonstrate that the 
cells, which were used in all following studies, are LECs, and not BEC or fibro-
blast, which may contaminate the cultures during the isolation process. In the 
next step, I analysed three human dermal (HD)-LEC lines by qRT-PCR and in-
vestigated the mRNA expression of WNT-related molecules. I used a pool of neu-
roblastoma cell lines, BECs and LECs as positive control. It has been shown that 
WNT signalling is high in many neuroblastoma cell lines (Jürgen Becker and 
Wilting, 2018), and Buttler et al. (2013) have previously shown that BEC and LY-
LECs also express several WNT-related molecules. The analysed HD-LECs 
show a wide variety of WNT-related mRNAs, and many of these could be verified 
at protein level with Western blots and immunocytology. Because of the fact that 
WNT5A is often found in the context of PCP, I was mainly interested in molecules 
that belong to the PCP pathway, and, in fact, many of them are expressed in HD-
LECs. I could also clearly confirm that HD-LECs express WNT5A. 
 
In e.g. Drosophila and mouse it has been shown that some PCP-molecules are 
expressed in a polarized manner. Thereby, Fzd and Vangl can form a so-called 
Fzd/PCP core complex (or Fzd-Vangl/PCP module in vertebrates). In general, 
Fzd and Vangl are localised at opposite cell membranes, and the two molecules 
interact with each other across neighbouring cells. There are also antagonistic 
effects of both molecules in the cell, which stabilises their polarized expression 
(reviewed in: Y Yang and Mlodzik (2015)). Because of the fact that endothelial 
cells cultured as a confluent monolayer show no strong polarization, I induced 
polarization. Therefore, I used the scratch assay, which is a migration assay. For 




Vladar et al. (2012) have shown that in tracheal epithelial cells of mice Fzd6 and 
Vangl1 are expressed in a polarized manner. Therefore, I used antibodies against 
FZDs and VANGL and stained migrating cells. I found polarized expression of 
FZD5 and VANGL2 in migrating HD-LECs. FZD5 is predominantly expressed in 
the trailing end of the cells and VANGL2 in the leading end. Both molecules do 
not show the expected clear expression at the cell membrane. This could be due 
to the fact that migration of cells in vitro differs from migration in vivo (Horwitz and 
Webb, 2003). And, the expression of Fzd6 and Vangl1 in tracheal epithelial cells 
was not a result of migration, but of pre-existing polarisation. Lim et al. (2016) 
showed nicely the expression of PRICKLE1 at the trailing end of human gastric 
cancer cells with the same antibody I used in my studies. Correspondingly, in 
migrating HD-LECs I observed PRICKLE1 expression at the trailing end. 
 
Taken together, my results clearly show that migrating LECs in scratch assays 




4.3 PORCN inhibition with LGK974 prevents 
WNT5A secretion in HD-LECs 
 
I used the PORCN inhibitor LGK974 in almost all of my studies to prevent WNT 
secretion. LGK974 was discovered by J Liu et al. (2013) and proposed as a pos-
sible drug for cancer treatment. Today, LGK974 is in phase 1 clinical trials for 
WNT-related cancers like melanoma, breast cancer and neuroepithelioma. 
LGK974 is a small molecule drug that inhibits PORCN. PORCN is a membrane-
bound O-acyltransferases located at the ER. It palmitoylates WNT ligands, and 
this palmitoylation is needed for the secretion of the WNT ligands.  
 
J Liu et al. (2013) showed in their studies that LGK974 is able to block secretion 
of Wnt1, -2, -3, -3A, -6, -7A, and -9A, and that this inhibition is highly specific for 
WNTs. They also stated that the inhibitory effect of LGK974 is consistent with the 
genetic loss of the PORCN phenotype (J Liu et al., 2013). They did not test if 
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LGK974 is able to block WNT5A secretion. Therefore, I tested if LGK974 inhibits 
WNT5A secretion in HD-LECs. I collected supernatants of HD-LECs, which had 
been treated for three days with 10 µM LGK974, concentrated them and analysed 
them with Western blots (WB) for the presences of WNT5A. The amount of 
WNT5A in the supernatants after LGK974 treatment was significantly decreased 
or almost absent, which clearly shows that LGK974 blocks WNT5A secretion. 
 
I had added LGK974 to the normal growth medium, which contains FBS. This led 
to a strong BSA fraction on the WB, and it appeared that this might have influ-
enced the results. Therefore, I repeated this analysis, and applied LGK974 to 
LECs in serum-free culture medium. To exclude any effects of culturing under 
serum-free conditions, I collected supernatants already after 24 h and repeated 
the experiment three times. Again, the application of LGK974 led also to a signif-
icant reduction of WNT5A in the supernatants, which clearly shows that LGK974 
blocks WNT5A secretion in LECs. 
 
I also tested the cell lysates of the treated LECs for WNT5A expression. I ex-
pected, like shown by J Liu et al. (2013) for Wnt3a, that no change in the amount 
of WNT5A occurred, or that eventually an increase would be seen, because of 
an accumulation of WNT5A in the cells. However, my studies show that LGK974 
also reduced the amount of WNT5A in the cells (in both conditions, w/wo serum). 
I can only speculate why LGK974 induced this effect. One reason could be the 
concentration of LGK974. I used 10 µM (the concentration that showed inhibitory 
effects in the in vitro assays), while the highest concentration used by J Liu et al. 
(2013) was 0,5 µM. However, they noted that there was no cytotoxicity up to 
20 µM. Furthermore, I treated the cells for up to three days, whereas J Liu et al. 
(2013) treated the cells in the reporter assay only for 24 h. Taken together, my 
studies show that LGK974 is able to inhibit WNT5A production and secretion in 
HD-LECs. 
 
LGK974 is not the only available PORCN inhibitor. There are others like Wnt-C59 
or IWP-3. I tested Wnt-C59 initially in the spheroid assays, and there I observed 
that LGK974 showed a stronger inhibitory effect. Therefore, I concentrated on 
LGK974 in all assays performed thereafter.  
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4.4 WNT signalling regulates various mecha-
nisms of lymphangiogenesis 
 
My studies on mouse dermis and the studies by Buttler et al. (2013) provided the 
hypothesis that in Wnt5a-null-mice the morphogenesis of lymphatic networks is 
defective. To analyse the underlying mechanisms more deeply, I used in vitro 
angiogenesis assays with human LECs and studied isolated aspects of lymphan-
giogenesis. There are established angiogenesis assays (for BECs) that provide 
a way of measuring these mechanisms e.g. proliferation, migration, sprouting, 
and network (tube) formation. I adapted these angiogenesis assays to lymphan-
giogenesis. I focussed on three different assays and analysed the influence of 
WNT signalling on lymphangiogenic aspects in greater detail. 
 
The first assay I performed was the spheroid assay, which measures sprouting 
of LECs. In this assay, EC are allowed to assemble into aggregates (spheroids). 
Then, these aggregates are transferred into extracellular matrix (ECM), like Mat-
rigel. The cells of the outer layer of the spheroids behave like tip-cells of devel-
oping/growing vessels and sprout into the ECM (Korff and Augustin, 1998). I per-
formed the initial assays with lymphangioma-derived LY-LECs (which were pre-
viously also used by Buttler et al. (2013)) and tested two PORCN inhibitors 
(Wnt-C59 and LGK974). Both of the inhibitors significantly prevented sprouting. 
This clearly shows that sprouting of LY-LECs is WNT-depended, which may pro-
vide a new therapeutic strategy for the lymphangioma patients. 
 
During my studies, our lab analysed the LY-LECs in greater detail and it was 
found that the cells possess a monoallelic activating mutation of the PIK3CA gene 
(Blesinger et al., 2018). Since there may be interactions between the PIK3CA 
pathway and the WNT-signalling pathway, I switched to LECs, which were iso-
lated from healthy donors. It was confirmed that the HD-LECs used in my further 





Therefore, I performed the spheroid assays with HD-LECs from a healthy donor. 
I observed that healthy LECs needed a stimulation with growth factors, especially 
VEGF-C, for sprouting. That sprouting of LECs can be stimulated with VEGF-C 
has been shown before (Bruyère et al., 2008). Like in the studies of Bruyère et 
al. (2008), I was able to block sprouting by application of soluble VEGF receptors, 
which bind VEGF-C. Interestingly, I could also inhibit the VEGF-C-induced 
sprouting with the two PORCN inhibitors (Wnt-C59 and LGK974). This again 
shows that sprouting of LECs is WNT-depended and supports the hypothesis of 
a connection/interplay between WNT and VEGF signalling (Olsen et al., 2017; 
Zhang et al., 2016). 
 
I further studied if the WNT-inhibition effects by LGK974 can be rescued by the 
application of recombinant WNT5A, but this was not successful. This could have 
multiple reasons. Most likely, WNT ligands are very sticky proteins with a lipid 
anchor, and signal only in direct cell contact or over short distances. There was 
probably not enough active WNT5A protein reaching the cell membranes through 
the Matrigel. WNTs are difficult to purify (van Amerongen et al., 2012) and ex-
pensive, therefore the studies could be repeated using supernatants from 
WNT5A overexpressing cells. 
 
The second mechanisms of lymphangiogenesis I investigated in greater detail 
with a focus on WNT signalling was migration. As mentioned before, migration is 
an important mechanism of lymphangiogenesis. To analyse migration, I per-
formed scratch assays. In this assay, a gap is scratched into a monolayer of cells 
and after a certain time-point the cells start to migrate towards this gap und close 
it. This type of migration also been called directed, or horizontal migration. I used 
several WNT-related activators and inhibitors in this assay and analysed their 
influence on migration. 
 
In a first step, I used the PORCN inhibitor LGK974 in this assay, and the results 
clearly show that horizontal migration of HD-LECs is WNT-dependent. In a sec-
ond step, I treated the HD-LECS for three days before scratching with LGK974 
(to prevent autocrine WNT signalling) and applied recombinant WN5A after 
scratching. I observed that WNT5A is able to rescue the inhibitory effect of 
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LGK974. That the LGK974 inhibition is reversible, has also been shown for 
Wnt3a by J Liu et al. (2013). This clearly shows that WNT5A mediates horizontal 
migration of HD-LECs. 
 
Discussing the scratch assays often leads to the question if the measured results 
exclusively reflect migration or if proliferation plays a role during the closure of 
the gap. It is known for quite some time that both migration and proliferation are 
important processes of vessel repair in vivo (Ausprunk and Folkman, 1977; 
Folkman and Haudenschild, 1980) and in vitro (Coomber and Gotlieb, 1990). It 
has also been shown that the first 3 - 4 rows of cells adjacent to the scratch are 
the ones that migrate (Ettenson and Gotlieb, 1994). To analyse the influence of 
proliferation, I also performed proliferation assays with all used drugs. These as-
says clearly reveal that HD-LECs need more than 24 h to double their cell num-
ber, and 24 h was the time-point where I stopped the scratch assays and ana-
lysed the scratch closure. 
 
I tested two concentrations (10 µM and 25 µM) of LGK974 in proliferation assays. 
Thereby, the lower concentration did not show significant effects on the prolifer-
ation of HD-LECs after 24 h, 48 h and 72 h. Cells treated with 25 µM showed 
reduced proliferation after 48 h and 72 h, but not after 24 h. These results are in 
line with the cytotoxicity level of 20 µM determined by J Liu et al. (2013). 
I also analysed the influence of pre-treatment with LGK974 and the application 
of recombinant WNT5A on proliferation. Again, there was no influence of both 
treatments on proliferation after 24 h and 48 h.  
 
Having shown that horizontal migration is WNT-mediated, I analysed the down-
stream signalling of WNT5A. WNT5A is the most prominent member of β-catenin-
independent WNT signalling pathway, but it has also been shown that WNT5A 
can activated the β-catenin-dependent WNT signalling pathway, depending upon 
the receptor context (AJ Mikels and Nusse, 2006). Therefore, in the next assays 
I applied two activators of the β-catenin-dependent WNT signalling pathway (IM-
12 and Bio) and one inhibitor of the β-catenin-dependent WNT signalling pathway 
(FH535). Both activators inhibited the horizontal migration of HD-LECs signifi-
cantly, whereas the application of the inhibitor of the β-catenin-dependent WNT 
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signalling did not influenced LEC migration. It is well known that the two WNT 
signalling pathways can antagonize each other (Torres et al., 1996). And there-
fore, my results imply that activation of the β-catenin-dependent pathway leads 
to an inhibition of the β-catenin-independent pathway, which in turn inhibits mi-
gration. Taken together, my results suggest that horizontal migration of HD-LECs 
is mediated through WNT5A, which actives the β-catenin-independent pathway. 
 
The inhibition of migration can also have a second reason. Both activators (IM-12 
and Bio) are GSK3 inhibitors. Previously, Grumolato et al. (2010); and Yamamoto 
et al. (2007) have shown that GSK3 can phosphorylate ROR receptors in a 
WNT5A-dependent manner. So, this can also mean that the GSK3 inhibition 
leads to an inhibition of the β-catenin-independent pathway.  
And GSK3 can phosphorylate more than 100 substrates (Beurel et al., 2015), 
which implies that inhibition of GSK3 can also interfere with other signalling path-
ways and cellular functions. 
 
Additionally, I always tested if these drugs used in the scratch assays had an 
influence on the proliferation of HD-LECs. Both activators of the β-catenin-de-
pendent signalling (IM-12 and Bio) did not change the proliferation significantly 
after 24 h. Interestingly, FH535, the inhibitor of the β-catenin-dependent signal-
ling significantly inhibited the proliferation after 24 h, but did not influenced the 
migration in the scratch assays. Again, this proves that the scratch assays per-
formed here exclusively measured migration and not proliferation. 
 
 
4.5 WNT5A mediates horizontal migration of 
HD-LECs via RAC and JNK 
 
Because of the fact that the hints that horizontal migration of HD-LECs is regu-
lated trough β-catenin-independent signalling via WNT5A, my next focus was to 
analyse the downstream signalling cascade of the WNT5A/β-catenin-independ-




For this purpose, I also used scratch assays and small molecule inhibitors. The 
first investigated downstream signalling molecule was ROCK. Numerous studies 
have shown that this kinase plays an important part in the control of migration 
(e.g. reviewed in Amano et al. (2010)). I tested two commonly used small mole-
cule inhibitors, Fasudil and Y-27632. Both of them did not block the migration of 
HD-LECs. I tested the drugs also in proliferation assays. Thereby, Y-27632 did 
and Fasudil did not reduced the proliferation of HD-LECs after 24 h. But, like for 
FH535, this clearly proves that the scratch assay specifically measures migration. 
 
There is a potential explanation why inhibition of ROCK does not influence the 
migration of HD-LECs. In fact, several studies have shown that ROCK mediates 
migration of cells by influencing the cytoskeleton, also called amoeboid-like mi-
gration (Sahai and Marshall, 2003). A second form of migration is called mesen-
chymal migration. During this type of migration the cells form protrusions/filopo-
dia, which has often been associated with RAC (Sahai and Marshall, 2003). And 
because of the fact that I observed filopodia in migrating HD-LECs, I assume that 
horizontal migration of HD-LECs represents mesenchymal type of migration. 
 
Therefore, in the next set of scratch assay I tested two RAC inhibitor – EHT 1864 
and NSC 234766. Both of the inhibitors significantly reduced the migration of 
HD-LECs. I performed proliferation assay as well. One inhibitor decreased prolif-
eration (NSC 234766), whereas EHT 1864 did not have any effects. Again, it is 
highly unlikely that this reduced proliferation influenced the measured migration.  
 
In the last set of scratch assays, I used inhibitors for JNK, a downstream signal-
ling molecule of RAC. Both of the inhibitors – SP600125 and JNK-IN-8 – reduced 
the migration of LECs significantly, and did not have any effect on proliferation. 
This clearly shows that horizontal migration of HD-LECs is regulated by RAC and 
JNK. 
To test if WNT5A is the ligand that activates this pathway, I used Western blot 
analysis and studied if JNK becomes phosphorylated after stimulation of 
HD-LECs with WNT5A. I used LGK974-pre-treated HD-LECs and stimulated 
them with recombinant WNT5A. Because of the fact that under normal growth 
conditions an overall phosphorylation of JNK was detectable, I had to starved the 
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cells for 24 h in serum-free medium before WNT5A application. The WB clearly 
showed that WNT5A induced a strong phosphorylation of JNK after 15 and 30 
minutes, whereas after 2 h the level of phosphorylation was nearly back to nor-
mal. This shows clearly that WNT5A is a potent activator of JNK in HD-LECs and 
that WNT5A mediates horizontal migration via RAC and JNK. 
 
That WNT5A mediates horizontal migration of cells via RAC and JNK is not a 
completely new finding. Nomachi et al. (2008) have shown that Wnt5a induces 
polarized migration of murine fibroblasts, which is mediated by JNK. However, it 
has not been shown before that horizontal migration of HD-LECs is mediated 
through this pathway.   
 
 
4.6 WNT5A increases network formation of 
HD-LECs in vitro 
 
In a third angiogenesis assay, I analysed the influence of WNT signalling on net-
work formation. Therefore, I used the widely accepted tube-formation assay. I 
used LGK974 pre-treated HD-LECs and then stimulated the cells with recombi-
nant WNT5A. The application of WNT5A led to a significant increase in cell-cov-
ered area, number of tubes, number of branching points, and total tube length. 
Interestingly, already the pre-treatment with LGK974 induced increased network 
formation. This was weaker than the stimulation with WNT5A, but also significant. 
I have no clear explanation for this. One hypothesis may be that network for-
mation of HD-LECs is regulated by an alternative pathway in the complete ab-
sence of WNT signalling. Probably, GSK3 is part of this pathway. As noted be-
fore, GSK3 is capable of phosphorylating numerous substrates. And in the ab-
sence of WNTs, when GSK3 is not inhibited by the WNT pathway, GSK3 may 
phosphorylate c-JUN (Sutherland, 2011), a transcription factor that is the down-
stream signalling molecule of JNK. Thereby, c-Jun regulates Receptor for Acti-
vated C Kinase 1 (RACK1) (López-Bergami et al., 2005), which in turn can regu-
late JNK. If this pathway induces network formation of LECs needs to be studied 
in future experiments.   
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4.7 WNTs regulate migration-associated and 
lymphangiocrine pathways 
 
In the last part of my studies I investigated, which genes were regulated by auto-
crine WNT signalling. For this part of my thesis I worked together with the TAL, 
Göttingen, and used mRNA-Sequencing. I analysed the regulation of genes in 
HD-LECs after treatment with LGK974, to inhibit autocrine WNT signalling of the 
cells. 
 
Treatment with LGK974 induced the differential expression of 116 genes. To get 
an overview of the function of the genes listed, a gene-set-enrichment analysis 
was performed. This analysis produced a list of 3 regulated gene sets. Of note, 
one of these was the gene set “GO: movement of cell or subcellular component”. 
This gene set revealed the down-regulation of migration-related transcripts after 
the application of LGK974, which is in line with my experimental studies. 
 
Three genes (IGF1, SPTA1, and SPTBN5) of the gene set caught my special 
attention. Insulin-like growth factor 1 (IGF-1) has important functions for the 
growth of the skeletal system. Mutations of the IGF-1 gene cause the Laron Syn-
drome, which is characterised by dwarfism (reviewed in Laron (2004)). Of note, 
Wnt5a-null mice have massive defects of the skeletal system. This implies that 
LECs control neighbouring cells (which is the function of the so-called angiocrine 
signalling), e.g. the cells of the developing skeleton in the limb buds. 
 
Additionally, I observed down-regulation of SPTA1 and SPTBN5, which encode 
for spectrins, a group of cytoskeletal proteins, which are important for migration 
and also for the stability of the cell membrane. 
 
In a first step, I started to validate the mRNAseq results. I repeated the experi-
ments and analysed the expression of these three genes with qRT-PCR. The 
results confirmed the mRNAseq results. Again, all three genes were down regu-
lated after treatment of HD-LECs with LGK974. 
Further analyses have to be performed to analysis these findings in greater detail.
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5 Summary and Conclusions 
 
Lymphangiogenesis – the development of lymphatic vessels – takes place in re-
sponse to lymphangiogenic growth factors during embryogenesis, wound heal-
ing, inflammation and cancer. It has been shown that WNT signalling plays im-
portant roles during embryonic development and cancer, and there are also a 
number of studies that have shown that WNT signalling controls angiogenesis. 
However, only very few investigations on WNT signalling on lymphangiogenesis 
exist, and these have not provided detailed analyses on the mechanisms how 
WNTs regulate the formation of lymphatics. 
 
 A previous study of my lab has revealed that Wnt5a, a member of the β-catenin-
independent Wnt pathway, is an essential regulator of lymphatic development in 
the dermis of mice. At embryonic day (ED) 18.5, Wnt5a-null-mice possess non-
functional, highly dilated lymphatics, in contrast to functional lymphatics with 
small lumen observed in Wnt5a+/- and wild-type mice.  
 
A) With whole-mount immunofluorescence staining, I show that Wnt5a-/- embryos 
exhibit blood-filled, often cyst-like lymphatics in their dermis, which fail to form 
proper interconnections. With fluorescence micro-lymphangiography I can show 
that these lymphatics are non-functional, whereas in Wnt5a+/- and wt-embryos 
lymphatic drainage is functional already at ED 17.5.  
 
B) With various immunostaining techniques, I demonstrate that dermal lymphat-
ics of murine embryos express several Wnt-related molecules, including Wnt5a 
and its Fzd receptors.  
 
C) With a newly developed ex vivo culture of embryonic dermis I show that Wnts, 
and especially Wnt5a, are important regulators of lymphangiogenesis. The appli-
cation of WNT5A protein to the dermis of ED 15.5 Wnt5a-null mice induces flow-
independent development of slender, elongated lymphatic networks after two 
days, in contrast to an immature lymphatic plexus in the controls. Thereby, mor-
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phology of individual LECs changes from round to elongated. Reversely, the ap-
plication of the PORCN-inhibitor LGK974 (which prevents the secretion of WNTs, 
which I confirmed for WNT5A in human LECs) to wild type-mouse dermis signif-
icantly disrupts lymphatic network maturation and elongation. 
 
D) Using various in vitro lymphangiogenesis assays with three different human 
LEC lines, I was able to show that WNTs, and prominently WNT5A, are potent 
regulators of lymphangiogenic mechanisms including sprouting, migration and 
tube formation. These mechanisms are independent of proliferation, which shows 
that non-canonical WNT signalling regulates various aspects of the morphogen-
esis of lymphatics. I also show that activation of the canonical pathway inhibits 
the effects of the non-canonical pathway.  
 
E) My studies on the intracellular cascade of WNT5A signalling in migrating LECs 
with scratch assays show that pharmacological inhibition of the RHO-GTPase 
RAC, or the c-Jun N-terminal kinase JNK significantly reduce migration, which 
leads to the assumption that WNT5A regulates morphogenesis of lymphatics via 
RAC and JNK. This is supported by the finding that WNT5A induces transient 
phosphorylation of JNK. 
 
F) Finally, global mRNAseq analyses of LECs show that WNTs regulate 116 
genes. Among these there are genes that control migration, but also angiocrine 
growth factors that indicate an active control of LECs for the growth of neighbour-
ing tissues. 
 
Taken together, my data clearly show that WNT signalling is an essential regula-





Additional Macrophotographs of a Wnt5a-null-mice and a wt-literate control 
(ED 16,5) are shown in Figure A- 1.  
 
Additional the 2way ANOVAs of proliferation studies are shown in Table A- 1 to  
Table A- 6. 
 
Table A-7 shows the all differentially regulated genes in HD-LECs treated with 




Figure A- 1: Macrophotographs of a Wnt5a-null-mouse embryo (upper row) and a littermate control 




Table A- 1: 2way ANOVA of proliferation studies with HD-LECs and the PORCN inhibitor LGK974. 
2way ANOVA of Proliferation Studies with LGK974 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4 
    
Number of comparisons per 
family 
2 
    
Alpha 0.05 
    













      
  0 h 
     
DMSO vs. LGK974 10 µM 0 -8.647 to 8.647 No ns >0.9999 
DMSO vs. LGK974 25 µM 0 -8.647 to 8.647 No ns >0.9999 
      
  24 h 
     
DMSO vs. LGK974 10 µM 2.385 -16.1 to 20.87 No ns >0.9999 
DMSO vs. LGK974 25 µM 12.42 -6.063 to 30.91 No ns 0.3216 
      
  48h 
     
DMSO vs. LGK974 10 µM -8.846 -27.33 to 9.641 No ns 0.7535 
DMSO vs. LGK974 25 µM 25.58 7.09 to 44.06 Yes ** 0.0028 
      
  72 h 
     
DMSO vs. LGK974 10 µM -9.409 -27.9 to 9.078 No ns 0.6668 





Table A- 2: 2way ANOVA of proliferation studies with LGK974 pre-treated (10 µM) HD-LECs and 
500ng/ml WNT5A. 
2way ANOVA of Proliferation Studies with WNT5A 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4 
    
Number of comparisons per 
family 2 
    
Alpha 0.05 
    













      
  0 h 
     
DMSO vs. LGK974 10 µMpre 2.50E-06 -26.1 to 26.1 No ns >0.9999 
DMSO vs. LGK974 10 µMpre  
+ WNT5A  9.17E-06 -26.1 to 26.1 No ns >0.9999 
      
  24 h 
     
DMSO vs. LGK974 10 µMpre 7.879 -18.22 to 33.98 No ns >0.9999 
DMSO vs. LGK974 10 µMpre  
+ WNT5A  5.53 -20.57 to 31.63 No ns >0.9999 
      
  48h 
     
DMSO vs. LGK974 10 µMpre 26.01 -0.0954 to 52.11 No ns 0.0512 
DMSO vs. LGK974 10 µMpre 
+ WNT5A  23.75 -2.352 to 49.85 No ns 0.0878 
      
  72h 
     
DMSO vs. LGK974 10 µMpre 42.22 16.11 to 68.32 Yes *** 0.0004 
DMSO vs. LGK974 10 µMpre 





Table A- 3: 2way ANOVA of proliferation studies with an inhibitor of the β-catenin-dependent WNT 
signalling pathway (FH535) and two activators (Bio and IM-12). 
2way ANOVA of Proliferation Studies with IM-12, Bio and FH535 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4 
    
Number of comparisons per 
family 
2 
    
Alpha 0.05 
    












Value       
  0 h 
     
DMSO vs. IM-12 10 µM 0 -12.67 to 12.67 No ns >0.9999 
DMSO vs. BIO 2 µM 0 -12.67 to 12.67 No ns >0.9999 
DMSO vs. FH535 10 µM 0 -12.67 to 12.67 No ns >0.9999 
      
  24 h 
     
DMSO vs. IM-12 10 µM -0.5325 -22.95 to 21.88 No ns >0.9999 
DMSO vs. BIO 2 µM 16.95 -5.464 to 39.37 No ns 0.2098 
DMSO vs. FH535 10 µM 26.09 3.677 to 48.51 Yes * 0.0161 
      
  48 h 
     
DMSO vs. IM-12 10 µM 26.95 4.535 to 49.36 Yes * 0.0121 
DMSO vs. BIO 2 µM 44.46 22.05 to 66.88 Yes *** <0.0001 
DMSO vs. FH535 10 µM 63.66 41.25 to 86.08 Yes *** <0.0001 
      
  72 h 
     
DMSO vs. IM-12 10 µM 74.84 52.43 to 97.26 Yes *** <0.0001 
DMSO vs. BIO 2 µM 66.27 43.85 to 88.68 Yes *** <0.0001 





Table A- 4: 2way ANOVA of proliferation studies with the ROCK inhibitors Y-27632 and Fasudil. 
2way ANOVA of Proliferation Studies with Y-27632 and Fasudil 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4     
Number of comparisons per 
family 2     
Alpha 0.05     













      
  0 h      
DMSO vs. Y-27632 50 µM 0 -11.69 to 11.69 No ns >0.9999 
DMSO vs. Fasudil 10 µM 0 -11.69 to 11.69 No ns >0.9999 
      
  24 h      
DMSO vs. Y-27632 50 µM 25.34 5.962 to 44.72 Yes ** 0.0069 
DMSO vs. Fasudil 10 µM -8.125 -29.6 to 13.35 No ns 0.7906 
      
  48 h      
DMSO vs. Y-27632 50 µM 51.24 31.7 to 70.78 Yes *** <0.0001 
DMSO vs. Fasudil 10 µM -26.31 -47.92 to -4.695 Yes * 0.0129 
      
  72 h      
DMSO vs. Y-27632 50 µM 67.89 48.19 to 87.59 Yes *** <0.0001 





Table A- 5: 2way ANOVA of proliferation studies with the RAC inhibitors EHT 1864 and NSC23766. 
2way ANOVA of Proliferation Studies with EHT 1864 and NSC23766 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4     
Number of comparisons per 
family 2     
Alpha 0.05     













      
  0 h      
DMSO vs. EHT 1864 10 µM -2.65 -27.96 to 22.66 No ns >0.9999 
DMSO vs. NSC23766 100 µM -3.448 -28.76 to 21.87 No ns >0.9999 
      
  24 h      
DMSO vs. EHT 1864 10 µM 24.46 -0.8565 to 49.77 No ns 0.0621 
DMSO vs. NSC23766 100ÂµM 31.29 5.976 to 56.6 Yes ** 0.0094 
      
  48 h      
DMSO vs. EHT 1864 10 µM 59 33.69 to 84.32 Yes *** <0.0001 
DMSO vs. NSC23766 100 µM 75.1 49.78 to 100.4 Yes *** <0.0001 
      
  72 h      
DMSO vs. EHT 1864 10 µM 83.65 58.34 to 109 Yes *** <0.0001 





Table A- 6: 2way ANOVA of proliferation studies with the JNK inhibitors SP600125 and JNK-IN-8. 
2way ANOVA of Proliferation Studies with SP600125 and JNK-IN-8 
Within each row, compare columns (simple effects within rows) 
      
Number of families 4     
Number of comparisons per 
family 2     
Alpha 0.05     













      
  0 h      
DMSO vs. SP600125 10 µM 0 -13.65 to 13.65 No ns >0.9999 
DMSO vs. JNK-IN-8 5 µM 0 -13.65 to 13.65 No ns >0.9999 
      
  24 h      
DMSO vs. SP600125 10 µM 8.298 -16.14 to 32.74 No ns 0.8913 
DMSO vs. JNK-IN-8 5 µM 6.213 -16.42 to 28.84 No ns >0.9999 
      
  48 h      
DMSO vs. SP600125 10 µM 30.78 5.87 to 55.69 Yes * 0.0113 
DMSO vs. JNK-IN-8 5 µM 45.58 22.59 to 68.57 Yes *** <0.0001 
      
  72 h      
DMSO vs. SP600125 10 µM 48.7 24.26 to 73.14 Yes *** <0.0001 





Table A-7: List of differentially regulated genes in HD-LECs treated with LGK974 compared to con-
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